7,990 Matching Annotations
  1. Nov 2021
    1. Pediatricians in the Austrian capital will authorize the off-label use of the BioNTech-Pfizer vaccine for children starting next Friday.
    1. The role of algorithms in propelling conspiracy theories and radicalisation has been brought into sharp focus by the interlocking crises of the past 12 months. Social media platforms have sought to tamp down on algorithmic recommendation of conspiracy theories and extremist content. This briefing uses Amazon’s book sales platform to illustrate how these problems with algorithmic recommendation extend far beyond the social media platforms. At the core of this issue is the failure to consider what a system designed to upsell customers on fitness equipment or gardening tools would do when unleashed on products espousing conspiracy theories, disinformation or extreme views. The entirely foreseeable outcome is that Amazon’s platform is inadvertently but actively promoting these ideas to their customers. The question of banning books is contentious and demands a broader conversation. However, there is a relatively simple solution to the problem of algorithmic amplification: turning recommendations off on these products, to avoid actively promoting harmful content and also avoid funnelling extra money into the pockets of its creators.
    1. There is a growing concern that e-commerce platforms are amplifying vaccine-misinformation. To investigate, we conduct two-sets of algorithmic audits for vaccine misinformation on the search and recommendation algorithms of Amazon—world’s leading e-retailer. First, we systematically audit search-results belonging to vaccine-related search-queries without logging into the platform—unpersonalized audits. We find 10.47% of search-results promote misinformative health products. We also observe ranking-bias, with Amazon ranking misinformative search-results higher than debunking search-results. Next, we analyze the effects of personalization due to account-history, where history is built progressively by performing various real-world user-actions, such as clicking a product. We find evidence of filter-bubble effect in Amazon’s recommendations; accounts performing actions on misinformative products are presented with more misinformation compared to accounts performing actions on neutral and debunking products. Interestingly, once user clicks on a misinformative product, homepage recommendations become more contaminated compared to when user shows an intention to buy that product.
    1. A recent flurry of social media activity regarding the Pfizer vaccine seems aimed at worsening vaccine hesitancy among Christians, particularly evangelicals.
    1. Objective: To offer a quantitative risk–benefit analysis oftwo doses of SARS-CoV-2 vaccination among adolescentsin England.Setting: England.Design: Following the risk–benefit analysis methodologycarried out by the US Centers for Disease Control, wecalculated historical rates of hospital admission, IntensiveCare Unit admission and death for ascertained SARS-CoV-2 cases in children aged 12–17 in England. We then usedthese rates alongside a range of estimates for incidence oflong COVID, vaccine efficacy and vaccine-induced myocar-ditis, to estimate hospital and Intensive Care Unit admis-sions, deaths and cases of long COVID over a period of 16weeks under assumptions of high and low case incidence.Participants: All 12–17 year olds with a record of con-firmed SARS-CoV-2 infection in England between 1 July2020 and 31 March 2021 using national linked electronichealth records, accessed through the British HeartFoundation Data Science Centre.Main outcome measures: Hospitalisations, Intensive CareUnit admissions, deaths and cases of long COVID avertedby vaccinating all 12–17 year olds in England over a 16-week period under different estimates of future caseincidence.Results: At high future case incidence of 1000/100,000population/week over 16 weeks, vaccination could avert4430 hospital admissions and 36 deaths over 16 weeks.At the low incidence of 50/100,000/week, vaccinationcould avert 70 hospital admissions and two deaths over16 weeks. The benefit of vaccination in terms ofhospitalisations in adolescents outweighs risks unless caserates are sustainably very low (below 30/100,000 teen-agers/week). Benefit of vaccination exists at any case ratefor the outcomes of death and long COVID, since neitherhave been associated with vaccination to date.Conclusions: Given the current (as at 15 September 2021)high case rates (680/100,000 population/week in 10–19year olds) in England, our findings support vaccination ofadolescents against SARS-CoV2.
    1. With Covid cases rising in the UK, should the government be moving forward with Plan B of restrictions?
    1. Nisreen A Alwan questions whether the current rates of covid infection in UK school children are acceptable when we have emerging evidence of the virus's lingering health effects
    1. Errors are an inevitable consequence of human fallibility, and researchers are no exception. Most researchers can recall major frustrations or serious time delays due to human errors while collecting, analyzing, or reporting data. The present study is an exploration of mistakes made during the data-management process in psychological research. We surveyed 488 researchers regarding the type, frequency, seriousness, and outcome of mistakes that have occurred in their research team during the last 5 years. The majority of respondents suggested that mistakes occurred with very low or low frequency. Most respondents reported that the most frequent mistakes led to insignificant or minor consequences, such as time loss or frustration. The most serious mistakes caused insignificant or minor consequences for about a third of respondents, moderate consequences for almost half of respondents, and major or extreme consequences for about one fifth of respondents. The most frequently reported types of mistakes were ambiguous naming/defining of data, version control error, and wrong data processing/analysis. Most mistakes were reportedly due to poor project preparation or management and/or personal difficulties (physical or cognitive constraints). With these initial exploratory findings, we do not aim to provide a description representative for psychological scientists but, rather, to lay the groundwork for a systematic investigation of human fallibility in research data management and the development of solutions to reduce errors and mitigate their impact.
    1. AbstractThe COVID-19 pandemic has revealed critical knowledge gaps in our understanding of and a need to update the traditional view of transmission pathways for respiratory viruses. The long-standing definitions of droplet and airborne transmission do not account for the mechanisms by which virus-laden respiratory droplets and aerosols travel through the air and lead to infection. In this Review, we discuss current evidence regarding the transmission of respiratory viruses by aerosols—how they are generated, transported, and deposited, as well as the factors affecting the relative contributions of droplet-spray deposition versus aerosol inhalation as modes of transmission. Improved understanding of aerosol transmission brought about by studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection requires a reevaluation of the major transmission pathways for other respiratory viruses, which will allow better-informed controls to reduce airborne transmission.
    1. SummaryBackgroundIn the USA, COVID-19 vaccines became available in mid-December, 2020, with adults aged 65 years and older among the first groups prioritised for vaccination. We estimated the national-level impact of the initial phases of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older.MethodsWe analysed population-based data reported to US federal agencies on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 50 years and older during the period Nov 1, 2020, to April 10, 2021. We calculated the relative change in incidence among older age groups compared with a younger reference group for pre-vaccination and post-vaccination periods, defined by the week when vaccination coverage in a given age group first exceeded coverage in the reference age group by at least 1%; time lags for immune response and time to outcome were incorporated. We assessed whether the ratio of these relative changes differed when comparing the pre-vaccination and post-vaccination periods.FindingsThe ratio of relative changes comparing the change in the COVID-19 case incidence ratio over the post-vaccine versus pre-vaccine periods showed relative decreases of 53% (95% CI 50 to 55) and 62% (59 to 64) among adults aged 65 to 74 years and 75 years and older, respectively, compared with those aged 50 to 64 years. We found similar results for emergency department visits with relative decreases of 61% (52 to 68) for adults aged 65 to 74 years and 77% (71 to 78) for those aged 75 years and older compared with adults aged 50 to 64 years. Hospital admissions declined by 39% (29 to 48) among those aged 60 to 69 years, 60% (54 to 66) among those aged 70 to 79 years, and 68% (62 to 73), among those aged 80 years and older, compared with adults aged 50 to 59 years. COVID-19 deaths also declined (by 41%, 95% CI –14 to 69 among adults aged 65–74 years and by 30%, –47 to 66 among those aged ≥75 years, compared with adults aged 50 to 64 years), but the magnitude of the impact of vaccination roll-out on deaths was unclear.InterpretationThe initial roll-out of the US COVID-19 vaccination programme was associated with reductions in COVID-19 cases, emergency department visits, and hospital admissions among older adults.FundingNone.
    1. During the COVID-19 pandemic, conspiracy theorists have exploited the provisional nature of scientific consensus and the realities of how science is conducted to paint scientists and public health leaders as malign actors. Download PDF
    1. Pregnant women are vulnerable to COVID-19, with increased risk of more severe illness and pregnancy complications, particularly if infected during the third trimester.1Allotey J Stallings E Bonet M et al.Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis.BMJ. 2020; 370m3320Crossref PubMed Scopus (16) Google Scholar Based on prior experience with vaccines in pregnancy, and with no hypothesised mechanisms for fetal harm, similar efficacy and side-effects to the non-pregnant population were anticipated with vaccination against SARS-CoV-2 in pregnancy. Current, albeit limited, data support this; no major safety signals were observed in animal reproductive toxicology studies or with post-marketing surveillance. However, until recently, there was little consensus regarding routine vaccination in pregnancy, and vaccine hesitancy in pregnant women remains high.2Skjefte M Ngirbabul M Akeju O et al.COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries.Eur J Epidemiol. 2021; 36: 197-211Crossref PubMed Scopus (25) Google Scholar
    1. (CNN)Join Big Bird, Elmo and Rosita for "The ABCs of Covid Vaccines: A CNN/Sesame Street Townhall for Families" this Saturday at 8:30 a.m. ET, hosted by CNN's Dr. Sanjay Gupta and Erica Hill. What questions do you or your kids have about Covid-19 vaccines? Share them below.
    1. During the COVID-19 pandemic social consequences in day-to-day decisions might not have been salient to the decider and thus egoistic. How can prosocial intentions be increased? In an experimental vignette study with N = 206, we compared the likelihood that parents send sick children to kindergarten after four interventions (general information about COVID-19, empathy, reflection of consequences via mental simulation, and control group). Independent of the intervention, empathic concern with individuals who were affected by COVID-19 and the salience of social consequences were high. The reported likelihood of sending a sick child to kindergarten was somewhat reduced in the control group and even more reduced in the reflection and empathy group, but not in the information group.
    1. Coronavirus Disease 2019 broke out in China at the end of 2019 and spread rapidly around the world. In response, many countries have adopted social distancing and lockdown measures. But restrictive measures resulted in many unwanted psychological consequences, including mental fatigue. Mental fatigue in turn is very likely to cause psychopathological disorders and cognitive malfunctions. A cognitive ability that is likely to be affected by mental fatigue is reasoning, while high reasoning ability is a prerequisite for compliance with restrictive measures. The present study aims to explore the association between mental fatigue and reasoning under the impact of long-term restrictive measures. The findings indicated that mental fatigue correlates negatively with cognitive reflection, while it has no significant association with general reasoning. The results also showed that mental fatigue correlates positively with the misperception of the preventive measures and negatively with the incomprehension of the restrictive measures. The implications of the results have been discussed.
    1. There is widespread concern about fake news and other misinformation circulating on social media. In particular, many argue that the context of social media itself may make people particularly susceptible to the influence of false claims. Here, we test that claim by asking whether simply considering whether to share news on social media reduces people’s ability to identify truth versus falsehood. In a large online experiment (N=3,157 Americans quota-matched to the national distribution of age, gender, ethnicity, and geographic region) examining COVID-19 and political news, we find support for this possibility. Compared to a baseline where participants judged only the accuracy of each headline, we observed worse truth discernment when participants also indicated their sharing intentions. Conversely, sharing discernment was substantially higher when participants also rated accuracy, relative to a baseline where sharing intentions were elicited without rating accuracy. These results suggest people may be particularly vulnerable to believing false claims on social media due to fundamental features of these platforms – which is particularly concerning given that it is hard to imagine social media without sharing.
    1. Trust in automation, is of concern in computer science and cognitive systems engineering, as well as the popular media (e.g., Chancey et al., 2015; Hoff and Bashir 2015; Hoffman et al., 2009; Huynh et al., 2006; Naone, 2009; Merritt and Ilgen, 2008; Merritt et al. 2013, 2015a; Pop et al. 2015; Shadbolt, 2002; Wickens et al. ,2015; Woods and Hollnagel 2006). Trust is of particular concern as more AI systems are being developed and tested (Schaefer et al., 2016).
    1. What was claimed £37 billion was found to pay Serco for a failed track and trace system. Our verdict £37 billion is the two-year budget for Test and Trace. The vast majority is spent on testing not tracing and does not go to Serco.
    1. What was claimed The Track and Trace app cost £37 billion. Our verdict The NHS Covid-19 app cost around £76 million in the first year. £37 billion is the total budget for NHS Test and Trace in its first two years.
    1. What was claimed £37 billion has been spent on NHS Test and Trace so far. Our verdict This is not true. £37 billion is the budget for the project’s first two years. We don’t know exactly how much was spent by early March, but it will be much less.
    1. Misinformation and disinformation campaigns have contributed to the death toll of the COVID-19 pandemic. Internists can effectively counter this and encourage vaccinations.
    1. To explain the observed phenomenon that most SARS-CoV-2 transmission occurs indoors whereas its outdoor transmission is rare, a simple macroscopic aerosol balance model is developed to link short- and long-range airborne transmission. The model considers the involvement of exhaled droplets with initial diameter ≤50 µm in the short-range airborne route, whereas only a fraction of these droplets with an initial diameter within 15 µm or equivalently a final diameter within 5 µm considered in the long-range airborne route. One surprising finding is that the room ventilation rate significantly affects the short-range airborne route, in contrast to traditional belief. When the ventilation rate in a room is insufficient, the airborne infection risks due to both short- and long-range transmission are high. A ventilation rate of 10 L/s per person provides a similar concentration vs distance decay profile to that in outdoor settings, which provides additional justification for the widely adopted ventilation standard of 10 L/s per person. The newly obtained data do not support the basic assumption in the existing ventilation standard ASHRAE 62.1 (2019) that the required people outdoor air rate is constant if the standard is used directly for respiratory infection control. Instead, it is necessary to increase the ventilation rate when the physical distance between people is less than approximately 2 m.
    1. Survey results show that many white-tailed deer, a familiar sight on US lawns and golf courses, have antibodies to the virus that causes COVID-19.
    1. It was the first country to vaccinate, the first to reopen, then the first to widely implement a booster shot. Now Israel is returning to life close to normal only six weeks after the peak of its worst COVID-19 wave yet.In mid-September, new infections of the Delta variant had surpassed 10,000 per day and hospitals were groaning under the pressure.But today, its restaurants are bustling, cinemas and theatres are packed, university lecture halls are full and the major airport is heaving.Deaths and new infections have plummeted to the single and triple digits, and the country will be welcoming overseas tourists from November 1.As Australia prepares to begin delivery of a third dose of the vaccine from next week, Israel's turnaround offers a glimpse into a possible future of the pandemic.So how did the country go from a cautionary tale to a success story in less than two months? The answer lies only partially in vaccines.
    1. Newly-published minutes from JCVI meetings show that the group first looked at whether letting 12 to 15-year-olds catch Covid naturally was better than vaccinating them on May 13 (shown above). It looked at a range of reasons against vaccinating people in the age group, which included the argument that natural infection might be better and less risky ‘Zero Covid’ scientists have slammed the Government’s coronavirus vaccine advisory panel as being ‘anti-vax’ for considering the benefits of herd immunity over vaccination in children.
    1. This week, two Tennessee state representatives introduced bills that would restrict the state's physician licensing board when attempting to discipline doctors who spread inaccurate information about COVID-19 and COVID vaccines. Katrina Green, MD, is concerned about the bills. She is an emergency physician in Nashville and Lawrenceburg, Tennessee, and also part of a group called Protect Our Care, which advocates for public health measures in the state.
    1. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 231 million people globally, with more than 4.7 million deaths recorded by the World Health Organization as of 26 September 2021. In response to the pandemic, some countries (New Zealand, Vietnam, Taiwan, South Korea and others) have pursued suppression strategies, so-called Zero COVID policies, to drive and maintain infection rates as close to zero as possible and respond aggressively to new cases. In comparison, European countries and North America have adopted mitigation strategies (of varying intensity and effectiveness) that aim primarily to prevent health systems from being overwhelmed. With recent advances in our understanding of SARS-CoV-2 and its biology, and the increasing recognition there is more to COVID-19 beyond the acute infection, we offer a perspective on some of the long-term risks of mutational escape, viral persistence, reinfection, immune dysregulation and neurological and multi-system complications (Long COVID).
    1. During a pandemic of an airborne disease like COVID-19, nearly all unvaccinated individuals will eventually be infected. Most children in Australia are currently unvaccinated. If they are not protected, 1-3% of unvaccinated Australian children may become hospitalised with COVID-19, and more may suffer from ongoing symptoms lasting for a year or more. Paediatric wards, hospitals and health systems may become overwhelmed. School closures and educational disruption are likely. We still do not know enough about the long-term risks posed by COVID-19 to children, but given what is currently known, and based on the precautionary principle, we should do what we can to protect children. San Francisco is an example where children have been successfully protected, whilst keeping schools open. Protecting children requires vaccinating children when possible, ensuring access to safe air through ventilation, and, where there is community transmission, using high quality masks, letting families make their own decisions about attending in-person school, and protecting children’s mental health.
    1. Today, the U.S. Food and Drug Administration authorized the emergency use of the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 to include children 5 through 11 years of age. The authorization was based on the FDA’s thorough and transparent evaluation of the data that included input from independent advisory committee experts who overwhelmingly voted in favor of making the vaccine available to children in this age group.
    1. COVID-19 pandemic has had a big impact on both adults' and children's everyday lives. The conversations about biological processes such as virus, illness, health have started to occur more frequently in daily interactions. Although there are many guidelines for parents about how to talk to their children about coronavirus, only a few studies examine what children are actually curious about coronavirus and how they make sense of the changes in their everyday lives. This study addresses this need by examining children's questions and parents' responses about the Covid-19 Pandemic in Turkey. Using an online survey, we asked 183 parents of 3 to 12-year-olds to report their children's questions about coronavirus and their answers to these questions. We analyzed children's questions and parents' responses using several content categories (Menendez et al., 2020). The majority of children's questions were about the nature of the virus (34%), followed by lifestyle changes (20%). Older children were more likely to ask about school/work and less likely to ask about lifestyle changes than younger children. Parents responded to children's questions by providing realistic explanations (48%) and reassurance (20%). Only 18% of children's questions were explanation-seeking "why" and "how" questions. Parents were more likely to provide explanations if children's questions were explanation-seeking. Family activities such as playing games and cooking were the most common coping strategies reported by parents (69.2%). The findings have important implications for children's learning about coronavirus and how adults can support children's understanding and help them develop coping strategies during the Covid-19 pandemic.
    1. The COVID-19 pandemic created heightened concern over SARS-CoV-2 transmission during athletic competitions and necessitated innovative mitigation solutions for protecting athletes, staff, and attendees.1,2 During sporting events, efforts like contact tracing pose unique challenges; namely, contact between athletes during play may be brief but recurring, while also challenging to track and triage, especially with interstate competitions. When the National Collegiate Athletic Association declared football a high-risk transmission sport, the Southeastern Conference (SEC), an intercollegiate athletic conference of 14 universities in 11 southern US states, responded with protocols aligned with US Centers for Disease Control and Prevention (CDC) guidance to monitor, manage, and mitigate SARS-CoV-2 exposure.3,4 In part, traditional contact tracing was augmented using wearable, remote proximity loggers to document interpersonal contacts. In this cohort study, we analyzed SARS-CoV-2 contact exposures and transmission among opposing team players during college football games as the COVID-19 pandemic surged.
    1. Vaccination efforts around the world are being restrained by a shortage of doses. Jane Feinmann looks at what is holding up the process
    1. Background A cluster of over a thousand infections with the SARS-CoV-2 delta variant was identified in a predominantly fully vaccinated population in Provincetown, Massachusetts in July 2021. Immune responses in breakthrough infections with the SARS-CoV-2 delta variant remain to be defined.Methods Humoral and cellular immune responses were assessed in 35 vaccinated individuals who were tested for SARS-CoV-2 in the Massachusetts Department of Public Health outbreak investigation.Results Vaccinated individuals who tested positive for SARS-CoV-2 demonstrated substantially higher antibody responses than vaccinated individuals who tested negative for SARS-CoV-2, including 28-fold higher binding antibody titers and 34-fold higher neutralizing antibody titers against the SARS-CoV-2 delta variant. Vaccinated individuals who tested positive also showed 4.4-fold higher Spike-specific CD8+ T cell responses against the SARS-CoV-2 delta variant than vaccinated individuals who tested negative.Conclusions Fully vaccinated individuals developed robust anamnestic antibody and T cell responses following infection with the SARS-CoV-2 delta variant. These data suggest important immunologic benefits of vaccination in the context of breakthrough infections.
    1. Vaccine hesitancy among the general population has become a primary concern for contending with the COVID pandemic as policymakers continue to exhaust options to incentivize individuals and vaccination uptake begins stagnating. The current study explores the relative contributions of several potential predictors of vaccine hesitancy. In an online cross-sectional survey study, 917 individuals from the U.S. were assessed on general and COVID-specific vaccine attitudes, COVID conspiracy and pseudoscientific beliefs, trust in various sources of information about COVID, and health and safety concerns surrounding the COVID vaccination. COVID vaccine attitudes, as well as general vaccine attitudes and behaviors, explained a substantial amount of variance, with trust in various information sources being moderately predictive of COVID vaccine attitudes. The data indicated a weak relationship between conspiracy and pseudoscientific beliefs, which disappeared altogether upon controlling for other variables. These findings suggest that efforts to confront vaccine hesitancy should go beyond confronting misinformation and consider initiatives aimed at trust enhancement and attitude change in vaccine-hesitant individuals.
    1. How do people reason in response to ambiguous messages shared by admirable individuals? Using behavioral markers and self-report questionnaires, in two experiments (N = 571) we examined the influence of speakers’ admirability on meaning-seeking and wise reasoning in response to pseudo-profound bullshit. In both studies, statements that sounded superficially impressive but lacked intent to communicate meaning generated meaning-seeking, but only when delivered by high admirability speakers (e.g., the Dalai Lama) as compared to low admirability speakers (e.g., Kim Kardashian). The effect of speakers’ admirability on meaning-seeking was unique to pseudo-profound bullshit statements and was absent for mundane (Study 1) and motivational (Study 2) statements. In Study 2, participants also engaged in wiser reasoning for pseudo-profound bullshit (vs. motivational) statements and did more so when speakers were high in admirability. These effects occurred independently of the amount of time spent on statements or the complexity of participants’ reflections. It appears that pseudo-profound bullshit can promote epistemic reflection and certain aspects of wisdom, when associated with an admirable speaker.
  2. Oct 2021
    1. Due to the COVID-19 pandemic and resultant school closures, social distancing measures, and restrictions placed on routine activities, the start of the academic year in September 2020 was a unique time for those transitioning to a new school. This study aimed to explore the experiences of parents who supported autistic children making a school transition in 2020, and to examine what impact parents perceived the COVID-19 pandemic had on their child’s school transition. Emphasis was placed on identifying facilitating factors that had benefitted school transitions, and barriers, which had negatively impacted these experiences. Semi-structured interviews were carried out with 13 parents of autistic children in the UK. Reflexive thematic analysis was carried out to identify themes in interview data. Parents reported a variety of experiences, and factors that were perceived as facilitatory to some were observed to be barriers by others. For some parents, the COVID-19 pandemic negatively impacted aspects of school transitions. For example, school closure in March 2020, being unable to visit their child’s new school, and social distancing measures were discussed as being barriers to an easy transition. However, other parents identified these factors as being facilitatory for their child or reported that these circumstances created opportunities to approach the school transition in a unique, improved manner. This paper sheds light on the heterogeneity of experiences and perceptions of parents of autistic children, and highlights the need to examine the impact of COVID-19 on school transitions, including practices which may be advantageous to retain.
    1. Previous literature highlights the crucial role of economic inequality in triggering a range of negative societal outcomes. However, the relationship between economic inequality and the proliferation of conspiracy beliefs remains unexplored. Here, we explore the endorsement of conspiracy beliefs as an outcome of objective country-level (Study 1a, 1b, 1c), perceived (Study 2), and manipulated economic inequality (Studies 3a, 3b, 4a, 4b). In the correlational studies, both objective and perceived economic inequality were associated with greater conspiracy beliefs. In the experiments, participants in the high (compared to the low) inequality condition were more likely to endorse conspiratorial narratives. This effect was fully mediated by anomie (Studies 3a, 3b) suggesting that inequality enhances the perception that society is breaking down (anomie), which in turn increases conspiratorial thinking, possibly in an attempt to regain some sense of order and control. Furthermore, the link between economic inequality and conspiracy beliefs was stronger when participants endorsed a conspiracy worldview (Studies 4a, 4b). Moreover, conspiracy beliefs mediated the effect of the economic inequality manipulation on willingness to engage in collective action aimed at addressing economic inequality. The results show that economic inequality and conspiracy beliefs go hand in hand: economic inequality can cause conspiratorial thinking and conspiracy beliefs can motivate collective action against economic inequality.
    1. Catalogue of billions of phrases from 107 million papers could ease computerized searching of the literature.
    1. In recent decades, the rapid growth of Internet adoption is offering opportunities for convenient and inexpensive access to scientific information. Wikipedia, one of the largest encyclopedias worldwide, has become a reference in this respect, and has attracted widespread attention from scholars. However, a clear understanding of the scientific sources underpinning Wikipedia's contents remains elusive. In this work, we explore Wikipedia's role in the public understanding of science from the perspective of its scientific sources. We rely on an open dataset of citations from Wikipedia, and use network analysis to map the relationship between Wikipedia articles and scientific journal articles. We find that most journal articles cited from Wikipedia belong to STEM fields, in particular biology and medicine (47.647.6\% of citations; 46.146.1\% of cited articles). Furthermore, Wikipedia's biographies play an important role in connecting STEM fields with the humanities, in particular history. Our results provide valuable insights into the reliance of Wikipedia on scientific sources, and its role in interconnecting knowledge across different topics.
    1. People who are fully vaccinated against covid-19 are far less likely to infect others, despite the arrival of the delta variant, several studies show. The findings refute the idea, which has become common in some circles, that vaccines no longer do much to prevent the spread of the coronavirus.
    1. Yet another version of the coronavirus is getting global attention, this one dubbed AY.4.2. It appears that it could be slightly more transmissible than the Delta variant — a marginal difference that experts say is more of a headache than a devastating gamechanger in the scope of the pandemic. Still, the emergence of AY.4.2 offers lessons about the ongoing evolution of the pathogen.
    1. The mystery of COVID’s origins has reignited a contentious debate about potentially risky studies and the fuzzy terminology that describes them.
    1. Fully vaccinated people with cancer who have no history of SARS-CoV-2 infection have much lower levels of neutralising antibodies against the delta variant (54%) than against the original SARS-CoV-2 virus (83%), a study has found.1The Capture study, conducted by the Francis Crick Institute and the Royal Marsden NHS Foundation Trust, analysed the immune responses of 585 patients with different types of cancer after they received two doses of the Pfizer-BioNTech or Oxford-AstraZeneca covid-19 vaccine.The researchers found that just 31% of infection naive patients with blood cancer developed neutralising antibodies against the delta variant, compared with 62% of patients with solid cancers. The response was 68% overall in patients who had received the Pfizer-BioNTech vaccine and 50% in recipients of the Oxford-AstraZeneca vaccine.Patients were recruited from May 2020 to June 2021. The median age was 60, and 60% were male. Overall, 31% (181/585) had prior confirmed SARS-CoV-2 infection. Around three quarters of participants (447/585) had a current diagnosis of a solid cancer, and 24% (138/585) had blood cancer.Rather than looking at covid-19 cases, the researchers used viral neutralisation assay tests to measure the levels of antibodies that block different variants of the virus. The researchers looked at whether patients had levels of neutralising antibodies that were sufficient to block at least 50% of virus infection under laboratory conditions.
    1. With FDA authorization for a kid-size COVID vaccine pending, a pediatrician and infectious-disease expert weighs in on what’s next.
    1. BackgroundThe SARS-CoV-2 delta (B.1.617.2) variant is highly transmissible and spreading globally, including in populations with high vaccination rates. We aimed to investigate transmission and viral load kinetics in vaccinated and unvaccinated individuals with mild delta variant infection in the community.MethodsBetween Sept 13, 2020, and Sept 15, 2021, 602 community contacts (identified via the UK contract-tracing system) of 471 UK COVID-19 index cases were recruited to the Assessment of Transmission and Contagiousness of COVID-19 in Contacts cohort study and contributed 8145 upper respiratory tract samples from daily sampling for up to 20 days. Household and non-household exposed contacts aged 5 years or older were eligible for recruitment if they could provide informed consent and agree to self-swabbing of the upper respiratory tract. We analysed transmission risk by vaccination status for 231 contacts exposed to 162 epidemiologically linked delta variant-infected index cases. We compared viral load trajectories from fully vaccinated individuals with delta infection (n=29) with unvaccinated individuals with delta (n=16), alpha (B.1.1.7; n=39), and pre-alpha (n=49) infections. Primary outcomes for the epidemiological analysis were to assess the secondary attack rate (SAR) in household contacts stratified by contact vaccination status and the index cases’ vaccination status. Primary outcomes for the viral load kinetics analysis were to detect differences in the peak viral load, viral growth rate, and viral decline rate between participants according to SARS-CoV-2 variant and vaccination status.FindingsThe SAR in household contacts exposed to the delta variant was 25% (95% CI 18–33) for fully vaccinated individuals compared with 38% (24–53) in unvaccinated individuals. The median time between second vaccine dose and study recruitment in fully vaccinated contacts was longer for infected individuals (median 101 days [IQR 74–120]) than for uninfected individuals (64 days [32–97], p=0·001). SAR among household contacts exposed to fully vaccinated index cases was similar to household contacts exposed to unvaccinated index cases (25% [95% CI 15–35] for vaccinated vs 23% [15–31] for unvaccinated). 12 (39%) of 31 infections in fully vaccinated household contacts arose from fully vaccinated epidemiologically linked index cases, further confirmed by genomic and virological analysis in three index case–contact pairs. Although peak viral load did not differ by vaccination status or variant type, it increased modestly with age (difference of 0·39 [95% credible interval –0·03 to 0·79] in peak log10 viral load per mL between those aged 10 years and 50 years). Fully vaccinated individuals with delta variant infection had a faster (posterior probability >0·84) mean rate of viral load decline (0·95 log10 copies per mL per day) than did unvaccinated individuals with pre-alpha (0·69), alpha (0·82), or delta (0·79) variant infections. Within individuals, faster viral load growth was correlated with higher peak viral load (correlation 0·42 [95% credible interval 0·13 to 0·65]) and slower decline (–0·44 [–0·67 to –0·18]).InterpretationVaccination reduces the risk of delta variant infection and accelerates viral clearance. Nonetheless, fully vaccinated individuals with breakthrough infections have peak viral load similar to unvaccinated cases and can efficiently transmit infection in household settings, including to fully vaccinated contacts. Host–virus interactions early in infection may shape the entire viral trajectory.FundingNational Institute for Health Research.
    1. WASHINGTON, Oct 27 (Reuters) - Workers at the leading U.S. meatpacking plants experienced cases and death from COVID-19 that were up to three times previous estimates, according to a report by the House Select Subcommittee on the Coronavirus Crisis seen by Reuters.
    1. he Independent SAGE +++ ‘We are following the ​science’ is the message the British public have been hearing from government since COVID-19 mitigating measures began. It says it is following the advice of the Scientific Advisory Group for Emergencies (SAGE). But the activities of the committee have been kept secret and excluded from scrutiny by the public or wider scientific community. In response, on Monday May 4, the Independent SAGE convened as a group of preeminent experts from the UK and around the world. The aim of the Independent SAGE was and is to provide robust, independent advice to HM Government with the purpose of helping the UK navigate COVID-19 whilst minimising fatalities. The Independent SAGE is chaired by former HM Government Chief Scientific Advisor Sir David King and draws on a range of international and British experts.
    1. LIVE NOW: Independent SAGE with experts discussing how we can build a better NHS and create a health, care and support system that is resilient to future shocks. Guests: @HelenKillaspy @AdelinaCoHe @drmarielouise @NeenaModi1 @RobertAunger & Dr Tony O’Sullivan
    1. After a summer of reports of breakthrough coronavirus infections, when it seemed that everyone knew someone who tested positive after vaccination, recently released federal data sheds light on how common these cases really were, how severe they became and who was most at risk.
    1. Determining policies to end the SARS-CoV-2 pandemic will require an understanding of the efficacy and effectiveness (hereafter, efficacy) of vaccines. Beyond the efficacy against severe disease and symptomatic and asymptomatic infection, understanding vaccine efficacy against virus transmission, including efficacy against transmission of different viral variants, will help model epidemic trajectory and determine appropriate control measures. Recent studies have proposed using random virologic testing in individual randomized controlled trials to improve estimation of vaccine efficacy against infection. We propose to further use the viral load measures from these tests to estimate efficacy against transmission. This estimation requires a model of the relationship between viral load and transmissibility and assumptions about the vaccine effect on transmission and the progress of the epidemic. We describe these key assumptions, potential violations of them, and solutions that can be implemented to mitigate these violations. Assessing these assumptions and implementing this random sampling, with viral load measures, will enable better estimation of the crucial measure of vaccine efficacy against transmission.
    1. Vaccine trials are generally designed to assess efficacy on clinical disease. The vaccine effect on infection, while important both as a proxy for transmission and to describe a vaccine’s total effects, requires frequent longitudinal sampling to capture all infections. Such sampling may not always be feasible. A logistically easy approach is to collect a sample to test for infection at a regularly scheduled visit. Such point or cross-sectional sampling does not permit estimation of classic vaccine effiacy on infection, as long duration infections are sampled with higher probability. Building on work by Rinta-Kokko and others (2009) we evaluate proxies of the vaccine effect on transmission at a point in time; the vaccine efficacy on prevalent infection and on prevalent viral load, VEPI and VEPV L, respectively. Longer infections with higher viral loads should have more transmission potential and prevalent vaccine efficacy naturally captures this aspect. We apply a proportional hazards model for infection risk and show how these metrics can be estimated using longitudinal or cross-sectional sampling. We also introduce regression models for designs with multiple cross-sectional sampling. The methods are evaluated by simulation and a phase III vaccine trial with PCR cross-sectional sampling for subclinical infection is analyzed.
    1. This report has been published to continue to share the detailed variant surveillance analyses which contribute to the variant risk assessments and designation of new VOCs and VUIs. The specialist technical briefings contain early data and analysis on emerging variants and findings have a high level of uncertainty. A separate report is published covering surveillance data on all other VOCs and VUIs. In summary: 1. There are 4 current variants of concern (VOCs) and 11 variants under investigation (VUIs) (Table 1). There are no new VOCs or VUIs in the UK classification since the last briefing. 2. Delta remains the predominant variant accounting for approximately 99.8% of sequenced cases in England as of 25 October 2021. 3. The Delta sublineage AY.4.2 (VUI-21OCT-01) accounts for a slowly increasing proportion of cases in the UK. It accounts for 8.5% of Delta cases in the most recent complete week of sequencing (4 October 2021 to 10 October 2021). In more recent weeks, sequencing data are incomplete, however AY.4.2 accounts for 10.3% of Delta cases in the week 11 October 2021 to 17 October 2021 and 11.3% in the week 18 October 2021 to 24 October 2021. 4. The growth rate and secondary attack rates have been refreshed with new data and the findings remain the same as last week. Estimated growth rates remain slightly higher for AY.4.2 than for Delta, and the household secondary attack rate is higher for AY.4.2 cases than for other Delta cases. 5. A preliminary rapid vaccine effectiveness analysis does not suggest a significant reduction in vaccine effectiveness for AY.4.2 compared to Delta. However, a further analysis more comprehensive analysis using the standard test negative case control study design is being undertaken. 6. The UKHSA variant definition for VUI-21OCT-01 currently has 95.2% sensitivity and 97.5% specificity for sequencing data outside of the UK (GISAID). 7. AY.4.2 live virus isolates have been obtained from residual biological materials and assays are in process. Pseudovirus work has been initiated. All risk assessments are published separately online, except for Gamma, which was published within Technical Briefing 7 and Alpha within Technical Briefing 9. As Delta is the dominant variant in the UK, epidemiological data in the weekly surveillance report is also relevant
    1. Rapid development of COVID-19 vaccines has helped mitigating SARS-CoV-2 spread, but more equitable allocation of vaccines is necessary to limit the global impact of the COVID-19 pandemic and the emergence of additional variants of concern. We have developed a COVID-19 vaccine candidate based on Newcastle disease virus (NDV) that can be manufactured at high yields in embryonated eggs. Here, we show that the NDV vector expressing an optimized spike antigen (NDV-HXP-S) is a versatile vaccine inducing protective antibody responses. NDV-HXP-S can be administered intramuscularly as inactivated vaccine or intranasally as live vaccine. We show that NDV-HXP-S GMP-produced in Vietnam, Thailand and Brazil is effective in the hamster model. Furthermore, we show that intramuscular vaccination with NDV-HXP-S reduces replication of tested variants of concerns in mice. The immunity conferred by NDV-HXP-S effectively counteracts SARS-CoV-2 infection in mice and hamsters.
    1. Vaccination reduces but does not eliminate the risk of covid-19 transmission within households, a study published in Lancet Infectious Diseases has found.1 It showed that one in four vaccinated household contacts of a covid-19 positive case became infected compared with 38% of unvaccinated contacts.
    1. BackgroundCOVID-19 is a pandemic respiratory and vascular disease caused by SARS-CoV-2 virus. There is a growing number of sensory deficits associated with COVID-19 and molecular mechanisms underlying these deficits are incompletely understood.MethodsWe report a series of ten COVID-19 patients with audiovestibular symptoms such as hearing loss, vestibular dysfunction and tinnitus. To investigate the causal relationship between SARS-CoV-2 and audiovestibular dysfunction, we examine human inner ear tissue, human inner ear in vitro cellular models, and mouse inner ear tissue.ResultsWe demonstrate that adult human inner ear tissue co-expresses the angiotensin-converting enzyme 2 (ACE2) receptor for SARS-CoV-2 virus, and the transmembrane protease serine 2 (TMPRSS2) and FURIN cofactors required for virus entry. Furthermore, hair cells and Schwann cells in explanted human vestibular tissue can be infected by SARS-CoV-2, as demonstrated by confocal microscopy. We establish three human induced pluripotent stem cell (hiPSC)-derived in vitro models of the inner ear for infection: two-dimensional otic prosensory cells (OPCs) and Schwann cell precursors (SCPs), and three-dimensional inner ear organoids. Both OPCs and SCPs express ACE2, TMPRSS2, and FURIN, with lower ACE2 and FURIN expression in SCPs. OPCs are permissive to SARS-CoV-2 infection; lower infection rates exist in isogenic SCPs. The inner ear organoids show that hair cells express ACE2 and are targets for SARS-CoV-2.ConclusionsOur results provide mechanistic explanations of audiovestibular dysfunction in COVID-19 patients and introduce hiPSC-derived systems for studying infectious human otologic disease.
    1. Story Highlights 36% of U.S. workers say their employer is requiring COVID-19 vaccine More employees continue to favor than oppose mandates Employees strongly opposed to mandates inclined to look for other jobs
    1. The spread of misinformation on social media and through other channels can affect COVID-19 vaccine confidence. Misinformation often arises when there are information gaps or unsettled science, as human nature seeks to reason, better understand, and fill in the gaps.
    1. In England, masks are expected and recommended in crowded and enclosed spaces – but not legally required. Many have abandoned them altogether. What would convince everyone to put them back on?
    1. Positief getest: 7.301 Totaal: 2.100.866 (+7.260 ivm -41 corr.) Perc. positief 19 okt - 25 okt: 15,7% Opgenomen: 113 Huidig: 659 (+2) Opgenomen op IC: 21 Huidig: 200 (+8) Overleden: 17 Totaal: 18.357Translated from Dutch by #COVID19NL Tested Positive: 7.301 Total: 2,100,866 (+7,260 due to -41 corr.) perc. positive Oct 19 - Oct 25: 15.7% Recorded: 113 Current: 659 (+2) Recorded on IC: 21 Current: 200 (+8)
    1. An international team of researchers want to find people who are genetically resistant to SARS-CoV-2, in the hope of developing new drugs and treatments.
    1. The Office for National Statistics (ONS) published a report based on an analysis of deaths involving COVID-19 that occurred between 2 January and 2 July 2021 in England, by vaccination status.
    1. New paper on 10,024 breakthrough infections shows that vaccination does not prevent #LongCovid.
    1. Another explainer for anyone interested in mortality analysis and how stats can be highly misleading. TLDR - The claim that you're more likely to die of any cause after vaccinated is flawed. It is slightly complex to explain but I will try my best. 1/13
    2. Another explainer for anyone interested in mortality analysis and how stats can be highly misleading. TLDR - The claim that you're more likely to die of any cause after vaccinated is flawed. It is slightly complex to explain but I will try my best. 1/13
    1. China (pop. 1.4 billion) is still pursuing a zero covid strategy, which means 20% of the world's population still officially lives under such a strategy https://nytimes.com/2021/10/27/world/asia/china-zero-covid-virus.html… (not endorsing strategy here, just pointing out that "return of Elvis" maybe warped comparison?)
    1. Health leaders agree that a world without COVID-19 will not be possible until everyone has equal access to vaccines. More than 4.6 million people have died from the virus since it swept across the globe from the beginning of 2020, but it’s expected that the rate of people dying will slow if more people are vaccinated. 
    1. As lockdowns ease in New South Wales, Victoria and the ACT, and people return to work and socialising, many of us will be mixing more with others, even though a section of the community is still unvaccinated.
    1. BackgroundHomeless-experienced populations are at increased risk of exposure to SARS-CoV-2 due to their living environments and face an increased risk of severe COVID-19 disease due to underlying health conditions. Little is known about COVID-19 testing and vaccination acceptability among homeless-experienced populations.ObjectiveTo understand the facilitators and barriers to COVID-19 testing and vaccine acceptability among homeless-experienced adults.DesignWe conducted in-depth interviews with participants from July to October 2020. We purposively recruited participants from (1) a longitudinal cohort of homeless-experienced older adults in Oakland, CA (n=37) and (2) a convenience sample of people (n=57) during a mobile outreach COVID-19 testing event in San Francisco.ParticipantsAdults with current or past experience of homelessness.ApproachWe asked participants about their experiences with and attitudes towards COVID-19 testing and their perceptions of COVID-19 vaccinations. We used participant observation techniques to document the interactions between testing teams and those approached for testing. We audio-recorded, transcribed, and content analyzed all interviews and identified major themes and subthemes.Key ResultsParticipants found incentivized COVID-19 testing administered in unsheltered settings and supported by community health outreach workers (CHOWs) to be acceptable. The majority of participants expressed a positive inclination toward vaccine acceptability, citing a desire to return to routine life and civic responsibility. Those who expressed hesitancy cited a desire to see trial data, concerns that vaccines included infectious materials, and mistrust of the government.ConclusionsParticipants expressed positive evaluations of the incentivized, mobile COVID-19 testing supported by CHOWs in unsheltered settings. The majority of participants expressed a positive inclination toward vaccination. Vaccine hesitancy concerns must be addressed when designing vaccine delivery strategies that overcome access challenges. Based on the successful implementation of COVID-19 testing, we recommend mobile delivery of vaccines using trusted CHOWs to address concerns and facilitate wider access to and uptake of the COVID vaccine.
    1. Freedom Day gave Covid-19 the freedom to spread again. Now, in the face of expert opinion, the prime minister drags his feet over the return of tougher restrictions.
    1. SummaryBackgroundEngland's COVID-19 roadmap out of lockdown policy set out the timeline and conditions for the stepwise lifting of non-pharmaceutical interventions (NPIs) as vaccination roll-out continued, with step one starting on March 8, 2021. In this study, we assess the roadmap, the impact of the delta (B.1.617.2) variant of SARS-CoV-2, and potential future epidemic trajectories.MethodsThis mathematical modelling study was done to assess the UK Government's four-step process to easing lockdown restrictions in England, UK. We extended a previously described model of SARS-CoV-2 transmission to incorporate vaccination and multi-strain dynamics to explicitly capture the emergence of the delta variant. We calibrated the model to English surveillance data, including hospital admissions, hospital occupancy, seroprevalence data, and population-level PCR testing data using a Bayesian evidence synthesis framework, then modelled the potential trajectory of the epidemic for a range of different schedules for relaxing NPIs. We estimated the resulting number of daily infections and hospital admissions, and daily and cumulative deaths. Three scenarios spanning a range of optimistic to pessimistic vaccine effectiveness, waning natural immunity, and cross-protection from previous infections were investigated. We also considered three levels of mixing after the lifting of restrictions.FindingsThe roadmap policy was successful in offsetting the increased transmission resulting from lifting NPIs starting on March 8, 2021, with increasing population immunity through vaccination. However, because of the emergence of the delta variant, with an estimated transmission advantage of 76% (95% credible interval [95% CrI] 69–83) over alpha, fully lifting NPIs on June 21, 2021, as originally planned might have led to 3900 (95% CrI 1500–5700) peak daily hospital admissions under our central parameter scenario. Delaying until July 19, 2021, reduced peak hospital admissions by three fold to 1400 (95% CrI 700–1700) per day. There was substantial uncertainty in the epidemic trajectory, with particular sensitivity to the transmissibility of delta, level of mixing, and estimates of vaccine effectiveness.InterpretationOur findings show that the risk of a large wave of COVID-19 hospital admissions resulting from lifting NPIs can be substantially mitigated if the timing of NPI relaxation is carefully balanced against vaccination coverage. However, with the delta variant, it might not be possible to fully lift NPIs without a third wave of hospital admissions and deaths, even if vaccination coverage is high. Variants of concern, their transmissibility, vaccine uptake, and vaccine effectiveness must be carefully monitored as countries relax pandemic control measures.FundingNational Institute for Health Research, UK Medical Research Council, Wellcome Trust, and UK Foreign, Commonwealth and Development Office.
    1. Many countries have seen sharp falls in the number of measles cases as a result of covid-19 controls, but the pandemic has also interrupted immunisation programmes
    1. Physical, psychological and cognitive symptoms have been reported as post-acute sequelae for COVID-19 patients but are also common in the general, uninfected population. We aimed to calculate the excess risk and identify patterns of 22 symptoms up to 12 months after COVID-19 infection. We followed more than 70,000 participants in an ongoing cohort study, the Norwegian Mother, Father and Child Cohort Study (MoBa) during the COVID-19 pandemic. Infected and non-infected cohort participants registered presence of 22 different symptoms in March 2021. One year after the initial infection, 13 of 22 symptoms were associated with SARS-CoV-2 infection, based on relative risks between infected and uninfected subjects. For instance, 17.4% of SARS-CoV-2 infected cohort participants reported fatigue that persist 12 months after infection, compared to new occurrence of fatigue that had lasted less than 12 months in 3.8% of non-infected subjects (excess risk 13.6%). The adjusted relative risk for fatigue was 4.8 (95 % CI 3.5 to 6.7). Two main underlying factors explained 50% of the variance in the 13 symptoms. Brain fog, poor memory, dizziness, heart palpitations, and fatigue had high loadings on the first factor, while shortness-of breath and cough had high loadings on the second factor. Lack of taste and smell showed low to moderate correlation to other symptoms. Anxiety, depression and mood swings were not strongly related to COVID-19. Our results suggest that there are clusters of symptoms after COVID-19 due to different mechanisms and question whether it is meaningful to describe long COVID as one syndrome.
    1. Following severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine1,2, European health authorities have recommended that patients under the age of 55 who received one dose of ChAdOx1-S-nCoV-19 vaccine receive a second dose of Pfizer BNT162b2 vaccine as a booster. However, the effectiveness and the immunogenicity of this vaccination regimen have not been formally tested. Here, we show that the heterologous ChAdOx1-S-nCoV-19/BNT162b2 combination confers better protection against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection than the homologous BNT162b2/BNT162b2 combination in a real-world observational study of healthcare workers (n=13121). To understand the underlying mechanism, we conducted a longitudinal survey of the anti-spike immunity conferred by each vaccine combination. Both combinations induced strong anti-spike antibody (Ab) responses but sera from heterologous vaccinated individuals displayed a stronger neutralizing activity, regardless of the SARS-CoV-2 variant. This enhanced neutralizing potential was correlated with increased frequencies of switched and activated memory B cells recognizing the SARS-CoV-2 Receptor Binding Domain (RBD). The ChAdOx1-S-nCoV-19 vaccine induced a weaker IgG response but a stronger T cell response than the BNT162b2 vaccine after the priming dose, which could explain the complementarity of both vaccines when used in combination. The heterologous vaccination regimen could therefore be particularly suitable for immune compromised individuals.
    1. VLA2001 successfully met both co-primary endpoints Superior neutralizing antibody titer levels compared to active comparator vaccine, AstraZeneca’s AZD1222 (ChAdOx1-S) Neutralizing antibody seroconversion rate above 95% VLA2001 induced broad T-cell responses with antigen-specific IFN-gamma-producing T-cells against the S, M and N proteins. VLA2001 was well tolerated, demonstrating a statistically significant better tolerability profile compared to active comparator vaccine
    1. In England, masks are expected and recommended in crowded and enclosed spaces – but not legally required. Many have abandoned them altogether. What would convince everyone to put them back on?
    1. Following the Surgeon General’s July 15 advisory on health misinformation and social media, President Joe Biden remarked that Facebook and other social media platforms are “killing people.” Though Biden quickly backpedaled on his remark, Facebook rebutted it, citing instead its own study that showed increasing “vaccine acceptance” by U.S. Facebook users.So, does Facebook play a role in COVID-19 misinformation? New survey results from researchers at Northwestern, Harvard, Northeastern and Rutgers universities show that it does.
    1. Department of Health bosses posted 223 fatalities today, up 23.2 per cent on last Tuesday 's figure of 181Cases also increased, with 43,738 new infections recorded, up 13.5 per cent on the 38,520 recorded last weekAnd the number of people being hospitalised spiked to 921 on Friday, the latest date data is available for
    1. Confusion and controversy surrounding COVID-19 vaccine boosters underscore the importance of journalists’ role in clearly explaining the scientific process to the public. Here are four tips to help you with your reporting.
    1. TORONTO -- With Health Canada expected to soon begin considering COVID-19 vaccine eligibility for children aged five to 11 years, a new survey by the Angus Reid Institute says that more than half of Canadian parents plan to give their kids the jab as soon as they get the green light. However, in a sign of the divided opinions on vaccinations across the country, nearly one-quarter say they will not vaccinate their elementary school-aged children even if the vaccines are approved for the age group. The survey found that 51 per cent of parents plan to get their children vaccinated as soon as it is approved, while 18 per cent said they plan to eventually get their children vaccinated, but would wait a while first. Twenty-three per cent said they will not get their children vaccinated, and nine per cent said they weren’t sure.
    1. WASHINGTON — Among scientists, there’s little debate: People who get sick with Covid-19 develop at least some protection against being infected in the future. But exactly how much protection they have, and how long it lasts, are the subjects of the country’s latest Covid-19 controversy. For the past month, university employees, professional athletes, and conservative lawmakers across the country have argued they should be exempted from increasingly strict vaccine mandates because, scientifically speaking, they don’t need them: They’re already protected by their body’s own immune response.
    1. A recent Editorial in this journal argued that, despite mixed reactions to the news that Pfizer-BioNTech's mRNA BNT162b2 vaccine was efficacious, immunogenic, and safe in children aged 12–15 years, “there might be a case for vaccinating children in the not-too-distant future”.1The Lancet Infectious DiseasesShould we vaccinate children against SARS-CoV-2?.Lancet Infect Dis. 2021; 21: 889Summary Full Text Full Text PDF PubMed Scopus (1) Google Scholar The Editorial concluded with “whether at present the children of high-income countries should be prioritised for vaccination over vulnerable adults in LMICs is a matter for serious ethical and practical debate”. Yet, we would argue these debates must remain fair to children and refrain from deprioritising children on ethical and evidential reasoning that betrays a bias towards adults.
    1. What is already known about this topic? Persons aged 12–18 years are eligible to receive COVID-19 vaccine. Currently, data are lacking on real-world vaccine effectiveness against COVID-19 hospitalization in adolescents. What is added by this report? Among hospitalized U.S. patients aged 12–18 years, vaccine effectiveness of 2 doses of Pfizer-BioNTech vaccine against COVID-19 hospitalization during June–September 2021, was 93% (95% confidence interval = 83%–97%). What are the implications for public health practice? This evaluation demonstrated that 2 doses of Pfizer-BioNTech vaccine were highly effective in preventing COVID-19 hospitalization among persons aged 12–18 years. Findings reinforce the importance of vaccination to protect U.S. youths against severe COVID-19.
    1. A video on Facebook, performed in the style of a rap battle and viewed more than 36,000 times, makes a number of misleading claims about Covid-19 and the vaccines.  In it, the self-proclaimed “truther” tells their “vaxxer” alter-ego that Covid-19 is as deadly as the flu, alludes to ivermectin as an effective treatment for the virus and describes side effects reported through the Yellow Card system.  These claims, alongside others made in the video, are identical to misinformation we have seen circulating throughout the pandemic and subsequent vaccination programme.  Here are the facts on six key points made during the video. 
    2. A video on Facebook, performed in the style of a rap battle and viewed more than 36,000 times, makes a number of misleading claims about Covid-19 and the vaccines. 
    1. With a dataset of testing and case counts from over 1,400 institutions of higher education (IHEs) in the United States, we analyze the number of infections and deaths from SARS-CoV-2 in the counties surrounding these IHEs during the Fall 2020 semester (August to December, 2020). We used a matching procedure designed to create groups of counties that are aligned along age, race, income, population, and urban/rural categories—socio-demographic variables that have been shown to be correlated with COVID-19 outcomes. We find that counties with IHEs that remained primarily online experienced fewer cases and deaths during the Fall 2020 semester; whereas before and after the semester, these two groups had almost identical COVID-19 incidence. Additionally, we see fewer deaths in counties with IHEs that reported conducting any on-campus testing compared to those that reported none. We complement the statistical analysis with a case study of IHEs in Massachusetts—a rich data state in our dataset—which further highlights the importance of IHE-affiliated testing for the broader community. The results in this work suggest that campus testing can itself be thought of as a mitigation policy and that allocating additional resources to IHEs to support efforts to regularly test students and staff would be beneficial to mitigating the spread of COVID-19 in the general population.
    1. Are workplace vaccine mandates prompting some employees to quit rather than get a shot? A hospital in Lowville, New York, for example, had to shut down its maternity ward when dozens of staffers left their jobs rather than get vaccinated. At least 125 employees at Indiana University Health resigned after refusing to take the vaccine. And several surveys have shown that as many as half of unvaccinated workers insist they would leave their jobs if forced to get the shot, which has raised alarms among some that more mandates could lead to an exodus of workers in many industries. New York, for example, is preparing for an exodus of health care workers – and may even call in the National Guard to help – as its vaccine mandate takes effect on Sept. 27, 2021.
    1. AbstractThe emergence of SARS-CoV-2 variants is jeopardizing the effectiveness of current vaccines and limiting the application of monoclonal antibody-based therapy for COVID-191,2. Here we analysed at single-cell level the memory B cells of five naive and five convalescent people vaccinated with the BNT162b2 mRNA vaccine to dissect the nature of the B cell and antibody response. Almost six-thousands cells were sorted, over three-thousand of them produced monoclonal antibodies against the spike protein and more than four hundred neutralized the original Wuhan SARS-CoV-2 virus. The B.1.351 (Beta) and B.1.1.248 (Gamma) variants showed to escape almost seventy per cent of these antibodies while a much smaller portion was impacted by the B.1.1.7 (Alpha) and B.1.617.2 (Delta) variants. The overall loss of neutralization was always significantly higher in the antibodies from naive people. In part this was due to the IGHV2-5;IGHJ4-1 germline, which was found only in convalescent people and generated potent and broadly neutralizing antibodies. Our data suggest that people that are seropositive following infection or primary vaccination will produce antibodies with increased potency and breadth and will be able to better control SARS-CoV-2 emerging variants.
    1. SummaryBackgroundVaccine effectiveness studies have not differentiated the effect of the delta (B.1.617.2) variant and potential waning immunity in observed reductions in effectiveness against SARS-CoV-2 infections. We aimed to evaluate overall and variant-specific effectiveness of BNT162b2 (tozinameran, Pfizer–BioNTech) against SARS-CoV-2 infections and COVID-19-related hospital admissions by time since vaccination among members of a large US health-care system.MethodsIn this retrospective cohort study, we analysed electronic health records of individuals (≥12 years) who were members of the health-care organisation Kaiser Permanente Southern California (CA, USA), to assess BNT162b2 vaccine effectiveness against SARS-CoV-2 infections and COVID-19-related hospital admissions for up to 6 months. Participants were required to have 1 year or more previous membership of the organisation. Outcomes comprised SARS-CoV-2 PCR-positive tests and COVID-19-related hospital admissions. Effectiveness calculations were based on hazard ratios from adjusted Cox models. This study was registered with ClinicalTrials.gov, NCT04848584.FindingsBetween Dec 14, 2020, and Aug 8, 2021, of 4 920 549 individuals assessed for eligibility, we included 3 436 957 (median age 45 years [IQR 29–61]; 1 799 395 [52·4%] female and 1 637 394 [47·6%] male). For fully vaccinated individuals, effectiveness against SARS-CoV-2 infections was 73% (95% CI 72–74) and against COVID-19-related hospital admissions was 90% (89–92). Effectiveness against infections declined from 88% (95% CI 86–89) during the first month after full vaccination to 47% (43–51) after 5 months. Among sequenced infections, vaccine effectiveness against infections of the delta variant was high during the first month after full vaccination (93% [95% CI 85–97]) but declined to 53% [39–65] after 4 months. Effectiveness against other (non-delta) variants the first month after full vaccination was also high at 97% (95% CI 95–99), but waned to 67% (45–80) at 4–5 months. Vaccine effectiveness against hospital admissions for infections with the delta variant for all ages was high overall (93% [95% CI 84–96]) up to 6 months.InterpretationOur results provide support for high effectiveness of BNT162b2 against hospital admissions up until around 6 months after being fully vaccinated, even in the face of widespread dissemination of the delta variant. Reduction in vaccine effectiveness against SARS-CoV-2 infections over time is probably primarily due to waning immunity with time rather than the delta variant escaping vaccine protection.FundingPfizer.
    1. SummaryBackgroundThe effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown.MethodsFrom individuals vaccinated with two doses against Covid-19 in Sweden until July 5, 2021 (N=3,445,061), we formed a study cohort including 94,569 individuals that had received heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination, 16,402 individuals that received heterologous ChAdOx1 nCoV-19 / mRNA-1273 prime-boost vaccination, and 430,100 individuals that received homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 prime-boost vaccination. In addition, 180,716 individuals were selected who were unvaccinated at the date of vaccination in the corresponding case. Unvaccinated individuals were censored at first dose of any vaccine. Baseline was the date of the second dose of any vaccine, with the same date in the corresponding unvaccinated individual. The outcome included incident symptomatic Covid-19 infection occurring >14 days after baseline.FindingsDuring a mean follow-up time of 76 (range 1-183) days, symptomatic Covid-19 infection was confirmed in 187 individuals with heterologous vaccine schedules (incidence rate: 2.0/100,000 person-days) and in 306 individuals from the unvaccinated control group (incidence rate: 7.1/100,000 person-days). The adjusted vaccine effectiveness was 67% (95% CI, 59-73, P<0.001) for heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination, and 79% (95% CI, 62-88, P<0.001) for heterologous ChAdOx1 nCoV-19 / mRNA-1273 prime-boost vaccination. When combined and analysed together, the two heterologous vaccine schedules had an effectiveness of 68% (95% CI, 61-74, P<0.001) which was significantly greater (Pinteraction<0.001) than the 50% effectiveness for homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 (95% CI, 41-58, P<0.001).InterpretationThe findings of this study suggest that the use of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination is an effective alternative to increase population immunity against Covid-19, including against the Delta variant which dominated the confirmed cases during the study period. These findings could have important implications for vaccination strategies and logistics, and consequently in the battle against the Covid-19 pandemic.Research in context Evidence before this studyAfter the rare thromboembolic events coupled to the first dose of vector-based vaccines towards Covid-19, heterologous vaccine schedules have been proposed as an option. Pre-clinical and clinical studies have suggested that heterologous vaccine schedules using ChAdOx1 nCoV-19 as the first dose, and either the BNT162b2 or mRNA-1273 as the second dose, elicit a stronger immune response compared with a homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 vaccine schedule. However, data on the potential effectiveness of heterologous vaccine schedules against symptomatic Covid-19 infection is lacking. Added value of this studyIn this study, heterologous Covid-19 vaccination using ChAdOx1 nCoV-19 as a first dose followed by either the BNT162b2 or mRNA-1273 as the second dose, was associated with 67% to 79% effectiveness against symptomatic Covid-19-infection. The effectiveness of the two heterologous schedules combined was significantly higher compared with the 50% effectiveness from homologous vaccination using ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19. Implications of all the available evidenceThe use of heterologous vaccine schedules appears to be an effective alternative for increasing population immunity against Covid-19, including against the Delta variant which dominated the confirmed cases during the study period. These results could have important implications for vaccination strategies and consequently in the battle against the pandemic.
    1. Importance  Recent data suggest a relatively low incidence of COVID-19 among children. The possible role that children attending primary school may play in the transmission of SARS-CoV-2 remains poorly understood.Objective  To gain a better understanding of the possible role of children in the transmission of SARS-CoV-2.Design, Setting, and Participants  This prospective cohort study was conducted from September 21 to December 31, 2020, in a primary school in Liège, Belgium, among a volunteer sample of 181 children, parents, and school employees.Exposures  Participants were tested for SARS-CoV-2 infection once a week for 15 weeks through throat washing, performed with 5 mL of saline and collected in a sterile tube after approximately 30 seconds of gargling. Quantitative reverse transcription–polymerase chain reaction was performed to detect SARS-CoV-2 infection.Main Outcomes and Measures  In case of test positivity, participants were asked to complete a questionnaire aimed at determining the timing of symptom onset and symptom duration. SARS-CoV-2 genetic sequencing was also performed. Confirmed cases were linked based on available information on known contacts and viral sequences.Results  A total of 181 individuals participated in this study, including 63 children (34 girls [54.0%]; mean [SD] age, 8.6 [1.9] years [range, 5-13 years]) and 118 adults (75 women [63.6%]; mean [SD] age, 42.5 [5.7] years [range, 30-59 years]). Forty-five individuals (24.9%) tested positive: 13 children (20.6%; 95% CI, 10.6%-30.6%) and 32 adults (27.1%; 95% CI, 19.1%-35.7%) (P = .34). Children were more often asymptomatic compared with adults (6 [46.2%; 95% CI, 19.1%-73.3%] vs 4 of 31 [12.9%; 95% CI, 1.3%-24.5%]; P = .04). The median duration of symptoms was shorter in children than in adults (0.00 days [IQR, 0.00-1.00 days] vs 15.00 days [IQR, 7.00-22.00 days]). A reconstruction of the outbreak revealed that most transmission events occurred between teachers and between children within the school. Of the observed household transmission events, most seemed to have originated from a child or teacher who acquired the infection at school.Conclusions and Relevance  Despite the implementation of several mitigation measures, the incidence of COVID-19 among children attending primary school in this study was comparable to that observed among teachers and parents. Transmission tree reconstruction suggests that most transmission events originated from within the school. Additional measures should be considered to reduce the transmission of SARS-CoV-2 at school, including intensified testing.
    1. Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world.
    1. (CNN)She was a frequent guest on The Oprah Winfrey Show -- an Ivy League-educated OB-GYN who often spoke about women's health and holistic medicine. She was a media darling, and in 2013 made Reader's Digest's annual list of 100 most trusted people in America. If you go to Dr. Christiane Northrup's Facebook page, her posts dispensing advice on health and aging to her 558,000 followers seem consistent with that persona of several years ago.But Northrup also uses her Facebook page to direct followers to Telegram, where another side of her is apparent. Here, on this platform with lax moderation, lies a miasma of misinformation and conspiracy theories.
    1. Description Contents Resources Courses About the Authors How do we make sense of complex evidence? What are the cognitive principles that allow detectives to solve crimes, and lay people to puzzle out everyday problems? To address these questions, David Lagnado presents a novel perspective on human reasoning. At heart, we are causal thinkers driven to explain the myriad ways in which people behave and interact. We build mental models of the world, enabling us to infer patterns of cause and effect, linking words to deeds, actions to effects, and crimes to evidence. But building models is not enough; we need to evaluate these models against evidence, and we often struggle with this task. We have a knack for explaining, but less skill at evaluating. Fortunately, we can improve our reasoning by reflecting on inferential practices and using formal tools. This book presents a system of rational inference that helps us evaluate our models and make sounder judgments. Introduces the notion of causal thinking and the key role it plays in how people reason about evidence Highlights the pitfalls and dangers when people evaluate complex evidence or deal with uncertainty and unreliable sources Introduces a formal framework for causal modelling to improve reasoning about complex cases
    1. A new mutated form of coronavirus that some are calling "Delta Plus" may spread more easily than regular Delta, UK experts now say. The UK Health Security Agency (UKHSA) has moved it up into the "variant under investigation" category, to reflect this possible risk. There is no evidence yet that it causes worse illness. And scientists are confident that existing vaccines should still work well to protect people. Although regular Delta still accounts for most Covid infections in the UK, cases of "Delta Plus" or AY.4.2 have been increasing. Latest official data suggests 6% of Covid cases are of this type.Experts say it is unlikely to take off in a big way or escape current vaccines. But officials say there is some early evidence that it may have an increased growth rate in the UK compared to Delta. "This sub-lineage has become increasingly common in the UK in recent months, and there is some early evidence that it may have an increased growth rate in the UK compared to Delta," the UKHSA said.
    1. EXECUTIVE SUMMARY The prophylactic Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) has been available in the US for prevention of Coronavirus Disease 2019 (COVID-19) as a two-dose primary series in individuals ≥16 years of age since December 2020 under an Emergency Use Authorization (EUA 27034; 11 December 2020). An amendment to the EUA was submitted to the FDA on 09 April 2021 and was authorized on 10 May 2021 to support emergency use as a two-dose primary series in individuals ≥12 years of age. Emergency Use Authorization of a single booster dose in at risk individuals1 ≥18 of age was granted on 22 September 2021. A Biologics License Application (BLA) was approved on 23 August 2021 in the United States (US) for BNT162b2 30 μg administration as a two-dose primary series to individuals ≥16 years of age. Approximately 1.4 billion doses of BNT162b2 have been distributed globally as of 31 August 2021.
    1. Workplace Covid-19 vaccination mandates have largely survived a first wave of legal challenges even as the number of lawsuits over them has soared with their expanded use.
    1. In July, 2021, another wave of COVID-19 began in the USA as the highly infectious delta (B.1.617.2) SARS-CoV-2 variant drove outbreaks predominantly affecting states with relatively low vaccination coverage. Some US states have shown the feasibility of rapidly achieving high vaccination coverage. Specifically, an average of 74·0% of adults had been fully vaccinated in Vermont, Connecticut, Massachusetts, Maine, and Rhode Island by July 31. By contrast, two states facing substantial delta-driven surges, Florida and Texas, had fully vaccinated only 59·5% and 55·8% of their adult residents, respectively.1The New York TimesSee how vaccinations are going in your county and state.https://www.nytimes.com/interactive/2020/us/covid-19-vaccine-doses.htmlDate: Dec 17, 2020Date accessed: August 5, 2021Google Scholar Here, we estimate the deaths, hospital admissions, and infections that could have been averted if Florida and Texas had matched the average vaccination pace of the top-performing states and vaccinated 74·0% of their adult populations by the end of July.We adapted our agent-based model of SARS-CoV-2 transmission2Moghadas SM Sah P Fitzpatrick MC et al.COVID-19 deaths and hospitalizations averted by rapid vaccination rollout in the United States.medRxiv. 2021; (published online July 8.) (preprint).https://doi.org/10.1101/2021.07.07.21260156Google Scholar,  3Shoukat A Vilches TN Moghadas SM et al.Lives saved and hospitalizations averted by COVID-19 vaccination in New York City.medRxiv. 2021; (published online July 18.) (preprint).https://doi.org/10.1101/2021.07.14.21260481Google Scholar to the demography, contact patterns, and age-stratified vaccination trajectories of Florida and Texas. We further accounted for the emergence and spread of the alpha (B.1.1.7), gamma (P.1), iota (B.1.526), and delta variants, in addition to the original strain.2Moghadas SM Sah P Fitzpatrick MC et al.COVID-19 deaths and hospitalizations averted by rapid vaccination rollout in the United States.medRxiv. 2021; (published online July 8.) (preprint).https://doi.org/10.1101/2021.07.07.21260156Google Scholar,  3Shoukat A Vilches TN Moghadas SM et al.Lives saved and hospitalizations averted by COVID-19 vaccination in New York City.medRxiv. 2021; (published online July 18.) (preprint).https://doi.org/10.1101/2021.07.14.21260481Google Scholar Vaccine efficacies against infection and symptomatic and severe disease for different vaccine types, each variant, and by vaccine dosage were parameterised from clinical studies (appendix pp 4–5). The model was calibrated to the reported incidence in each state between Oct 1, 2020, and Aug 31, 2021 (appendix p 6). Using the calibrated model, we evaluated the impact of enhanced vaccination rollout by scaling the daily vaccine doses distributed to achieve 74·0% coverage of fully vaccinated adults by July 31, 2021, and continued with the associated daily rates of vaccine rollout. We then simulated the epidemiological trajectories of outbreaks in Florida and Texas and compared them with the observed cases, hospital admissions, and deaths in these two states from Dec 12, 2020, to Aug 31, 2021.We found that enhanced vaccination would have markedly blunted the increase in cases, hospital admissions, and deaths in Florida and Texas (figure; appendix p 6). From the start of vaccination on Dec 12, 2020, until Aug 31, 2021, Florida had reported 2 221 520 COVID-19 cases and Texas had reported 2 142 833. Achieving 74·0% vaccination coverage by July 31 and continuing with the associated daily rate would have averted 664 007 additional cases (95% credible interval [CrI] 419 219–848 020) in Florida and 647 906 additional cases (507 298–789 885) in Texas (appendix p 7). By Aug 31, the enhanced vaccination in Florida would have reduced hospital admissions by 61 327 (95% CrI 49 723–73 501) and deaths by 16235 (13 243–19 473). The reduction in hospital admissions in Texas during the same period would have been 37 587 (95% CrI 31 575–44 659) and the reduction in deaths would have been 6353 (5227–7501). Collectively, these two states could have averted more than 95 000 hospital admissions and 22 000 deaths had they reached the vaccination coverage achieved by the top five states and continued at the same pace until Aug 31, 2021.FigureModel projections of daily deaths in (A) Florida and (B) TexasShow full captionBlack lines show mean estimates, with uncertainty bounds of simulations shown in grey shaded areas. Red dots are reported data. Blue lines and shaded areas show the model projections for mean estimates and uncertainty bounds under the counterfactual scenario of enhanced vaccination with 74·0% coverage of adults by July 31, 2021. The purple lines and shaded areas show the model projections for mean estimates and uncertainty bounds under the scenario of a 50% increase in daily vaccination rate starting from Sept 1, 2021. All uncertainty bounds are 95% credible intervals.View Large Image Figure ViewerDownload Hi-res image Download (PPT)We further projected the epidemiological impact of a 50% increase in the daily vaccination rate in Florida and Texas compared with the status quo from Sept 1, 2021 (figure; appendix p 6). Our projections suggest that between then and Oct 31, 2021, such acceleration of vaccination would prevent more than 26 000 cases and 1200 deaths in the two states.Hospitals and intensive care units in several US states are currently overwhelmed by a surge in symptomatic COVID-19 illness almost entirely among unvaccinated individuals. The combination of relatively lower vaccination rates in southern and central US states, especially among younger people, is even more concerning as schools return to in-person classes and non-pharmacological measures such as mask wearing and physical distancing are relaxed. As the pandemic continues, efforts to increase vaccination will be crucial to preventing future SARS-CoV-2 variants that can fuel additional waves of severe illness, hospital admissions, and deaths.This work was supported by The Commonwealth Fund, of which ECS is an employee. All other authors declare no competing interests. SMM also acknowledges support by the Canadian Institutes of Health Research (OV4 – 170643, COVID-19 Rapid Research) and the Natural Sciences and Engineering Research Council of Canada, Emerging Infectious Disease Modelling, MfPH grant. The computational codes for reproducibility are available at https://github.com/thomasvilches/multiple_strains/tree/TXnFL.
    1. The Covid-19 vaccines are not like those Monday morning surprise dishes at your local restaurant. They aren’t like some of those less regulated dietary supplements that may secretly contain Viagra or steroids either. No, Covid-19 vaccines should not have unexpected ingredients. To make sure people know what they are getting, the U.S. Food and Drug Administration (FDA) has posted an ingredient list for the Pfizer/BioNTech Covid-19 vaccine on its website. So, has the Centers for Disease Control and Prevention (CDC).
    1. What was claimed Vaccines contain graphene oxide. Our verdict False. The Covid-19 vaccines do not contain graphene oxide.
    1. Importance  Short-term and long-term persistent postacute sequelae of COVID-19 (PASC) have not been systematically evaluated. The incidence and evolution of PASC are dependent on time from infection, organ systems and tissue affected, vaccination status, variant of the virus, and geographic region.Objective  To estimate organ system–specific frequency and evolution of PASC.Evidence Review  PubMed (MEDLINE), Scopus, the World Health Organization Global Literature on Coronavirus Disease, and CoronaCentral databases were searched from December 2019 through March 2021. A total of 2100 studies were identified from databases and through cited references. Studies providing data on PASC in children and adults were included. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines for abstracting data were followed and performed independently by 2 reviewers. Quality was assessed using the Newcastle-Ottawa Scale for cohort studies. The main outcome was frequency of PASC diagnosed by (1) laboratory investigation, (2) radiologic pathology, and (3) clinical signs and symptoms. PASC were classified by organ system, ie, neurologic; cardiovascular; respiratory; digestive; dermatologic; and ear, nose, and throat as well as mental health, constitutional symptoms, and functional mobility.Findings  From a total of 2100 studies identified, 57 studies with 250 351 survivors of COVID-19 met inclusion criteria. The mean (SD) age of survivors was 54.4 (8.9) years, 140 196 (56%) were male, and 197 777 (79%) were hospitalized during acute COVID-19. High-income countries contributed 45 studies (79%). The median (IQR) proportion of COVID-19 survivors experiencing at least 1 PASC was 54.0% (45.0%-69.0%; 13 studies) at 1 month (short-term), 55.0% (34.8%-65.5%; 38 studies) at 2 to 5 months (intermediate-term), and 54.0% (31.0%-67.0%; 9 studies) at 6 or more months (long-term). Most prevalent pulmonary sequelae, neurologic disorders, mental health disorders, functional mobility impairments, and general and constitutional symptoms were chest imaging abnormality (median [IQR], 62.2% [45.8%-76.5%]), difficulty concentrating (median [IQR], 23.8% [20.4%-25.9%]), generalized anxiety disorder (median [IQR], 29.6% [14.0%-44.0%]), general functional impairments (median [IQR], 44.0% [23.4%-62.6%]), and fatigue or muscle weakness (median [IQR], 37.5% [25.4%-54.5%]), respectively. Other frequently reported symptoms included cardiac, dermatologic, digestive, and ear, nose, and throat disorders.Conclusions and Relevance  In this systematic review, more than half of COVID-19 survivors experienced PASC 6 months after recovery. The most common PASC involved functional mobility impairments, pulmonary abnormalities, and mental health disorders. These long-term PASC effects occur on a scale that could overwhelm existing health care capacity, particularly in low- and middle-income countries.
    1. Objectives To compare the effectiveness of the BNT162b2 mRNA (Pfizer-BioNTech) and the ChAdOx1 (Oxford-AstraZeneca) COVID-19 vaccines against infection and COVID-19 disease in health and social care workers.Design Cohort study, emulating a comparative effectiveness trial.Setting Linked primary care, hospital, and COVID-19 surveillance records available within the OpenSAFELY-TPP research platform.Participants 317,341 health and social care workers vaccinated between 4 January and 28 February 2021, registered with a GP practice using the TPP SystmOne clinical information system in England, and not clinically extremely vulnerable.Interventions Vaccination with either BNT162b2 or ChAdOx1 administered as part of the national COVID-19 vaccine roll-out.Main outcome measures Recorded SARS-CoV-2 positive test, or COVID-19 related Accident and Emergency attendance or hospital admission occurring within 20 weeks of vaccination.Results The cumulative incidence of each outcome was similar for both vaccines during the first 20 weeks post-vaccination. The cumulative incidence of recorded SARS-CoV-2 infection 6 weeks after vaccination with BNT162b2 was 19.2 per 1000 people (95%CI 18.6 to 19.7) and with ChAdOx1 was 18.9 (95%CI 17.6 to 20.3), representing a difference of -0.24 per 1000 people (95%CI -1.71 to 1.22). The difference in the cumulative incidence per 1000 people of COVID-19 accident and emergency attendance at 6 weeks was 0.01 per 1000 people (95%CI -0.27 to 0.28). For COVID-19 hospital admission, this difference was 0.03 per 1000 people (95%CI -0.22 to 0.27).Conclusions In this cohort of healthcare workers where we would not anticipate vaccine type to be related to health status, we found no substantial differences in the incidence of SARS-CoV-2 infection or COVID-19 disease up to 20 weeks after vaccination. Incidence dropped sharply after 3-4 weeks and there were very few COVID-19 hospital attendance and admission events after this period. This is in line with expected onset of vaccine-induced immunity, and suggests strong protection against COVID-19 disease for both vaccines.
    1. The government’s Covid dashboard has just been updated, and it shows that there have been 52,009 new coronavirus cases. That is the highest daily total on this measure, and the first time the daily tally has topped 50,000, for more than three months. Daily new cases were last at this level on 17 July, when 54,674 were recorded.
    1. Since the early days of the COVID-19 pandemic, media and policy makers have speculated about herd immunity and the threshold for numbers of immune citizens needed for reaching it. What are the effects of such numerical goals on willingness to vaccinate? In a large representative sample of unvaccinated Swedes we find that giving a low (60%) compared to a high (90%) threshold have direct effects on beliefs about reaching herd immunity and beliefs about how many others will get vaccinated. Presenting the high threshold makes people believe that herd immunity is harder to reach, compared to the low threshold, yet at the same time people also believe that a higher number of the population will get vaccinated. Since these beliefs affects willingness to vaccinate in opposite directions, some individuals are encouraged and others discouraged depending on the threshold presented. This has consequences for ongoing COVID-19 vaccination and future vaccination campaigns
    1. A new report in MMWR this week provides a stark reminder. COVID vaccines save lives – especially for teens with obesity and other medical conditions. The study analyzed 464 patients 12 to 18 years old. Of those, 179 were hospitalized with COVID-19 and 285 were case controls. Nearly three quarters (72 percent) of these patients had at least one underlying health condition, including obesity. But vaccination with two doses of the Pfizer-BioNTech vaccine proved to be 93% effective for preventing hospitalization with COVID-19. Furthermore, it was 100 percent effective in preventing ICU admission and death. None of the ICU admissions or deaths occurred in vaccinated teens.
    1. Twitter shared its own research today that showed its algorithms amplify right-leaning political content more than left-leaning.
    1. When veteran scientist Craig Rayner saw Australian laboratory results had been published that suggested the drug ivermectin could potentially fight COVID-19, he felt a sense of dread.The experienced drug developer was aware experiments with ivermectin had been performed. Two weeks earlier, researchers at the Monash Biomedicine Discovery Institute had sought his opinion on some laboratory tests that showed the drug could stop the SARS-Cov-2 virus from growing in cell culture.
    1. Accurate and near real-time data about the trajectory of the COVID-19 pandemic have been crucial in informing mitigation policies. Because choosing the right mitigation policies relies on an accurate assessment of the current state of the local epidemic, the potential ramifications of misinterpreting data are serious. Each data source has inherent biases and pitfalls in interpretation. The more data sources that are interpreted in combination, the easier it is to detect genuine changes in an epidemic. Recently, in many countries, this has involved disentangling the varying impact of rising but heterogeneous vaccination rates, relaxation of mitigations, and the emergence of new variants such as Delta.
    1. Coronavirus disease 2019 (COVID-19) can damage cerebral small vessels and cause neurological symptoms. Here we describe structural changes in cerebral small vessels of patients with COVID-19 and elucidate potential mechanisms underlying the vascular pathology. In brains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected individuals and animal models, we found an increased number of empty basement membrane tubes, so-called string vessels representing remnants of lost capillaries. We obtained evidence that brain endothelial cells are infected and that the main protease of SARS-CoV-2 (Mpro) cleaves NEMO, the essential modulator of nuclear factor-κB. By ablating NEMO, Mpro induces the death of human brain endothelial cells and the occurrence of string vessels in mice. Deletion of receptor-interacting protein kinase (RIPK) 3, a mediator of regulated cell death, blocks the vessel rarefaction and disruption of the blood–brain barrier due to NEMO ablation. Importantly, a pharmacological inhibitor of RIPK signaling prevented the Mpro-induced microvascular pathology. Our data suggest RIPK as a potential therapeutic target to treat the neuropathology of COVID-19.
    1. Multiple summer events, including large indoor gatherings, in Provincetown, Massachusetts (MA), in July 2021 contributed to an outbreak of over one thousand COVID-19 cases among residents and visitors. Most cases were fully vaccinated, many of whom were also symptomatic, prompting a comprehensive public health response, motivating changes to national masking recommendations, and raising questions about infection and transmission among vaccinated individuals. To characterize the outbreak and the viral population underlying it, we combined genomic and epidemiological data from 467 individuals, including 40% of known outbreak-associated cases. The Delta variant accounted for 99% of sequenced outbreak-associated cases. Phylogenetic analysis suggests over 40 sources of Delta in the dataset, with one responsible for a single cluster containing 83% of outbreak-associated genomes. This cluster was likely not the result of extensive spread at a single site, but rather transmission from a common source across multiple settings over a short time. Genomic and epidemiological data combined provide strong support for 25 transmission events from, including many between, fully vaccinated individuals; genomic data alone provides evidence for an additional 64. Together, genomic epidemiology provides a high-resolution picture of the Provincetown outbreak, revealing multiple cases of transmission of Delta from fully vaccinated individuals. However, despite its magnitude, the outbreak was restricted in its onward impact in MA and the US, likely due to high vaccination rates and a robust public health response.
    1. Finding the origin location of an infectious disease outbreak quickly is crucial in mitigating its further dissemination. Current methods to identify outbreak locations early on rely on interviewing affected individuals and correlating their movements, which is a manual, time-consuming, and error-prone process. Other methods such as contact tracing, genomic sequencing or theoretical models of epidemic spread offer help, but they are not applicable at the onset of an outbreak as they require highly processed information or established transmission chains. Digital data sources such as mobile phones offer new ways to find outbreak sources in an automated way. Here, we propose a novel method to determine outbreak origins from geolocated movement data of individuals affected by the outbreak. Our algorithm scans movement trajectories for shared locations and identifies the outbreak origin as the most dominant among them. We test the method using various empirical and synthetic datasets, and demonstrate that it is able to single out the true outbreak location with high accuracy, requiring only data of 𝑁=4N=4N=4 individuals. The method can be applied to scenarios with multiple outbreak locations, and is even able to estimate the number of outbreak sources if unknown, while being robust to noise. Our method is the first to offer a reliable, accurate out-of-the-box approach to identify outbreak locations in the initial phase of an outbreak. It can be easily and quickly applied in a crisis situation, improving on previous manual approaches. The method is not only applicable in the context of disease outbreaks, but can be used to find shared locations in movement data in other contexts as well.
    1. Estimates based on viral evolution forecast a 50% risk 17 months after a first infection without measures such as masking and vaccination.
    1. Nearly everyone in Iran has been infected by the coronavirus at some point during the covid-19 pandemic, and some have caught the virus more than once, but the country still hasn’t achieved herd immunity. Instead, Iran is seeing a punishing new wave of deaths driven by the delta variant.
    1. Members of the Independent Scientific and Advisory Group for Emergencies may be surprised to find themselves portrayed as rebel scientists (doi:10.1136/bmj.n2504),1 and critics may see this as yet another reason to distrust or dismiss this self-appointed group. But rebels they have been, and we need rebels if things are to change. Opinions differ as to whether iSAGE has made a positive difference in the UK’s response to the covid-19 pandemic, but it has definitely achieved one thing. Through its frequent and open engagement with the public, and by always showing its workings, it has forced the government’s advisers to be more transparent and accountable (doi:10.1136/bmj.n2452),2 and this has changed the nature and raised the quality of the debate.
    1. Background. Why does adversity lead to mental health complaints in some, but not others? Individual differences in the development of depressive complaints are related to the regulation of affect states. The COVID-19 pandemic has caused a prolonged period of perturbations to the daily lives of people across the globe, providing an unparalleled opportunity to investigate how fluctuations in positive and negative affect relate to the evolution of mood complaints. Methods. 228 participants from the Boston College daily sleep and well-being survey completed at least 20 assessments of positive and negative affect and depression complaints between March 20th 2020 and June 26th 2020. We explored affect trajectories throughout this period and estimated longitudinal multilevel network models. Furthermore, we investigated how individual network structures relate to changes in depression severity over time. Results. On average, positive affect was reported somewhat higher than negative affect. However, when separating affect trajectories based on the individuals’ depressive complaints, we identified that individuals consistently experiencing depressive complaints report higher levels of negative affect compared with positive affect. Contrary, individuals consistently reporting no depressive complaints show opposite results. Furthermore, we found many and strong associations in the multilevel network between the distinct affect states and depressive complaints. Lastly, we established that the higher the connectivity of an individual’s network, the larger their change in depressive complaints is. Conclusions. We conclude that affect fluctuations are directly related to the development of depressive complaints, both within- and across individuals, and both within a single measurement moment and over time.
    1. Preventing the negative impacts of major, intersectional U.S. social issues hinges on personal concern and willingness to take action. We examined social comparison of COVID-19, racial injustice, and climate change during Fall 2020. Participants in a U.S. university sample (n = 288), reported personal levels of concern and action taken on these issues, and estimated their peers’ concern and action. Participants accurately estimated similar levels of personal and peer concern for racial injustice and climate change, but overestimated peer concern for COVID-19. At higher personal concern levels, people estimated that they took greater action than peers for all issues. Exploratory analyses found that perceived personal control over social issues increased participants’ concern and action for racial injustice and climate change, but yielded no change for COVID-19. This suggests that issue-specific features, including perceived controllability, may drive people to differently assess their experience of distinct social issues relative to peers.
    1. That behavioral sciences are overrepresented by some countries, in terms of samples and authors, is a well-documented finding. Considering the immediate policy implications, the present study aimed to scope whether this is true in the context of understanding the effects of the coronavirus as well. We assessed relevant preprints with “coronavirus” or “COVID-19” as keywords published on PsyArxiv between March-April, 2020, as well as between May-December, 2020 in terms of samples, participants, and authors. We found that some countries, such as the US, were overrepresented in both waves; papers based on authors from such countries, and employing samples from such countries were also more likely to be published in journals with higher impact factors, and were also more likely to be cited more. Implications, especially regarding a reductionist bifurcation of research as “WEIRD” or “non-WEIRD,” are discussed.
    1. In March 2020, the Global Consortium of Chemosensory Research (GCCR) was founded by chemosensory researchers to address then emerging reports of unusual smell and taste dysfunction arising from the SARS-CoV-2 pandemic. Over the next year, the GCCR used a highly collaborative model, along with contemporary Open Science practices, to produce multiple high impact publications on chemosensation and COVID19. This invited manuscript describes the founding of the GCCR, the tools and approaches it used, and a summary of findings to date. These findings are contextualized within a summary of some of the broader insights about chemosensation (smell, taste, and chemesthesis) and COVID19 gained over the last 18 months, including potential mechanisms of loss. Also, it includes a detailed discussion of some current Open Science approaches and practices used by the GCCR to increase transparency, rigor, and reproducibility.
    1. For a very long time in the COVID-19 crisis, behavioural change leading to physical distancing behaviour was the only tool at our disposal to mitigate virus spread. In this large-scale naturalistic experimental study we show how we can use behavioural science to find ways to promote the desired physical distancing behaviour. During seven days in a supermarket we implemented different behavioural interventions: (i) rewarding customers for keeping distance; (i) providing signage to guide customers; and (iii) altering shopping cart regulations. We asked customers to wear a tag that measured distances to other tags using ultra-wide band at 1Hz. In total N = 4,232 customers participated in the study. We compared the number of contacts (< 1.5 m, corresponding to Dutch regulations) between customers using state-of-the-art contact network analyses. We found that rewarding customers and providing signage increased physical distancing, whereas shopping cart regulations did not impact physical distancing. Rewarding customers moreover reduced the duration of remaining contacts between customers. These results demonstrate the feasibility to conduct large-scale behavioural experiments that can provide guidelines for policy. While the COVID-19 crisis unequivocally demonstrates the importance of behaviour and behavioural change, behaviour is integral to many crises, like the trading of mortgages in the financial crisis or the consuming of goods in the climate crisis. We argue that by acknowledging the role of behaviour in crises, and redefining this role in terms of the desired behaviour and necessary behavioural change, behavioural science can open up new solutions to crises and inform policy. We believe that we should start taking advantage of these opportunities.
    1. The COVID-19 outbreak imposed an overwhelming workload as well as emotional burdens on healthcare professionals (HCPs). In May 2020, an online survey was administered to HCPs in Italy to assess the pandemic’s psychological impact and to investigate possible predictive factors that led to individual differences. Female and younger respondents, especially those operating in northern Italy experienced more frequently negative emotional states such as irritability, anxiety, loneliness, and insecurity. However, positive feelings, first of all solidarity, were also reported especially by female and older workers. The majority of the negative as well as positive emotional states were experienced almost equally by both doctors and nurses, and independently of the operational unit in which they operated. Our findings can provide useful information in planning more tailored psychological interventions to support this category of workers.
    1. The COVID-19 outbreak has led to major restrictions globally, affecting people’s psychosocial health and their health behaviors. Thus, the purpose of this scoping review was to summarize the available research regarding the nature-health-association in the COVID-19 context. Keywords related to natural environments and COVID-19 were combined to conduct a systematic online search in six major databases. Eligibility criteria were a) published since 2020 with data collected in the COVID-19 context b) peer-reviewed, c) original empirical data collected on human participants, d) investigated the association between natural environments and psychosocial health or health behavior, and e) English, German, or Scandinavian language. Out of 8,568 articles being obtained, we identified 82 relevant articles representing 80 unique studies. Most studies focused on adults in the general population and were predominantly conducted in the USA and Europe. Overall, the findings tentatively indicate that nature mitigates the impact of COVID-19 on psychological health and physical activity. Through thematic analysis of the extracted data, three primary themes were identified: 1) type of nature assessed, 2) psychosocial health and health behaviors investigated, and 3) heterogeneity in the nature-health relationship. Research gaps in the COVID-19 context were identified regarding I) nature characteristics that promote psychosocial health and health behaviors, II) investigations of digital and virtual nature, III) psychological constructs relating to mental health promotion, IV) health behaviors other than physical activity, V) underlying mechanisms regarding heterogeneity in the nature-health relationship based on human, nature, and geographic characteristics, and VI) research focusing on vulnerable groups. Overall, natural environments demonstrate considerable potential in buffering the impact of stressful events on a population level on mental health. However, future research is warranted to fill the mentioned research gaps and to examine the long-term effects of nature exposure during COVID-19.
    1. Synthesizing research on wisdom and a real-world practitioner intervention, we develop/test a strategy for presenting political views that fosters cross-partisan respect. This strategy—balanced pragmatism—combines two aspects of “wise reasoning:” balancing multiple interests and seeking pragmatic solutions. Studies 1-3 (N = 1187) demonstrate that participants respected out-group political elites more when they used balanced pragmatism vs. other forms of messaging. Studies 4-6 (N = 671) extend the usefulness of balanced pragmatism to everyday political disagreements: cross-partisan comments about divisive issues (i.e., guns and immigration) generated more respect when they used balanced pragmatism vs. logical analysis. Strikingly, people were as willing to discuss politics with disagreeing opponents who used balanced pragmatism as they were agreeing ingroup members. Mediation analyses suggest that balanced pragmatism improves cross-partisan respect by making opponents seem more moral, authentic, and rational. Results highlight connections between political/moral psychology and wisdom research, and the fruitfulness of scientist-practitioner collaborations.
    1. Ensuring widespread public exposure to best-science guidance is crucial in a crisis, e.g. Covid-19, climate change. Mapping the emitter-receiver dynamics of Covid-19 guidance among 87 million Facebook users, we uncover a multi-sided battle over exposure that gets lost well before the pandemic's official announcement. By the time Covid-19 vaccines emerge, the mainstream majority -- including many parenting communities -- have moved even closer to more extreme communities. The hidden heterogeneity explains why Facebook's own promotion of best-science guidance also missed key audience segments. A simple mathematical model reproduces these exposure dynamics at the system level. Our findings can be used to tailor guidance at scale while accounting for individual diversity, and to predict tipping point behavior and system-level responses to interventions.
    1. Background Knowing your audience is the first step in an effective public health communication campaign. While previous studies provide broad categories of public intentions to get a COVID-19 vaccine, few systematically segment and identify effective ways to engage with distinct publics to improve COVID-19 vaccine uptake. Methods Using data from a national sample of Australian public (N = 1054) and based on the Theory of Planned Behaviour, a latent class analysis of 23 items was undertaken to identify COVID-19 audience segments for potential future message targeting. Findings We found five different segments on COVID-19 vaccine intentions: Vaccine enthusiasts (28%), supporters (26%), socials (20%), hesitant (15%), and sceptics (10%). While the vaccine hesitants have concerns about safety and side-effects of the vaccine, the sceptics hold additional concerns about the need for a vaccine and dismiss the health risks. Vaccine socials hold less favourable attitudes towards a COVID-19 vaccine but are willing to get one to protect others. These audience segments differ on demographic variables and in their level of trust in mainstream media, scientists and health experts, social media, and family and friends. In particular, we found the most vulnerable—the poor and undereducated—may need further help in understanding the need and importance of COVID-19 vaccination. Interpretation Understanding the COVID-19 vaccine attitudinal and information seeking characteristics of these sub-publics will help inform appropriate messaging campaigns to reach out to vaccine hesitant and sceptics for promoting vaccination. It provides insight into what types of message framing may be effective, through which platforms messages should be provided, and by which trusted sources.
    1. Are parents and families struggling with the ongoing demands of the pandemic, or are parents resilient and adjusted to the ‘new normal’? Assessing average risk versus resilience requires examining how parents and families have fared across the pandemic, beyond the initial months examined in prior investigations. The current research examines average levels of risk versus resilience in parents’ health and functioning over the first 1.5 years of the pandemic. Parents (N = 272) who had completed general assessments prior to the pandemic completed reassessments of psychological and physical health, couple and family functioning, and parenting within two lockdowns involving mandatory home confinement: at the beginning of the pandemic (26 March–28 April 2020) and 17 months later (18 August–21 September 2021). On average, parents exhibited declines in psychological and physical health (greater depressive symptoms; reduced well-being, energy and physical health) and in couple and family functioning (reduced commitment and family cohesion; greater problem severity and family chaos). By contrast, parent-child relationship quality and parenting practices were resilient with no average differences across the lockdowns. Declines in health and couple/family functioning generally occurred irrespective of pre-existing vulnerabilities (poor health and functioning prior to the pandemic) and external stress (reported impact of the pandemic). Partner support, however, tended to buffer declines in couple/family functioning. The results emphasize that attending to the challenges parents and couples face in the home will be important targets to mitigate the ongoing risks of the pandemic to parents’ and children’s well-being.
    1. Companies are updating vaccines and testing them on people to prepare for whatever comes next in the pandemic.
    1. Individuals who experience threats to their social needs may attempt to avert further harm by condemning wrongdoers more severely. Three pre-registered studies tested whether threatened social esteem is associated with increased moral condemnation. In Study 1 (N = 381) participants played a game in which they were socially included or excluded and then evaluated the actions of moral wrongdoers. We observed an indirect effect: Exclusion increased social needs-threat, which in turn increased moral condemnation. Study 2 (N = 428) was a direct replication, and also showed this indirect effect. Both studies demonstrated the effect across five moral foundations, which was most pronounced for harm violations. Study 3 (N= 102) examined dispositional concerns about social needs threat, namely social anxiety, and showed a positive correlation between this trait and moral judgments. Overall, results suggest threatened social standing is linked to moral condemnation, presumably because moral wrongdoers pose a further threat when one’s ability to cope is already compromised.
    1. The emerging SARS-CoV-2 variants may potentially have enhanced transmissibility and virulence of the virus, and impacts on performance of diagnostic tools and efficacy of vaccines. Genomic surveillance provides an opportunity to detect and characterize new mutations early enough for effective deployment of control strategies. Here, genomic data from Germany and United Kingdom were examined for genetic diversity by assessing gene mutations and inferring phylogeny. Delta variant sublineages were grouped into seven distinct clusters of spike mutations located in N-terminal domain of S1 region (T95I, D138H, *D142G, Y145H and A222V) and S2 region (T719I and *N950D). The most predominant cluster was T95I mutation, with the highest frequencies (71.1% - 83.9%) in Wales, England and Scotland, and the least frequencies (8.9% - 12.1%) in Germany. Two mutations, *D142G and *N950D here described as *reverse mutations and T719I mutation, were largely unique to Germany. In a month, frequencies of D142G had increased from 55.6% to 67.8 % in Germany. Additionally, a cluster of D142G+T719I/T mutation went up from 27.7% to 34.1%, while a T95I+ D142G+N950D/N cluster rose from 19.2% to 26.2%. Although, two distinct clusters of T95I+D138H (2.6% - 3.8%) and T95I+Y145H+A222V (2.5% - 8.5%) mutations were present in all the countries, they were most predominant in Wales and Scotland respectively. Results suggest divergent evolutionary trajectories between the clusters of D142G mutation and those of T95I mutation. These findings provide insights into underlying dynamics of evolution of the delta variant. Future studies may evaluate the epidemiological and biological implications of these sublineages.
    1. Misinformation is running rampant. To slow this infodemic, researchers are tracking how it spreads on social media.
    1. Billions of shots of China’s CoronaVac and Sinopharm vaccines have been given globally, but studies have questioned the length of protection they offer.
    1. A new study reports that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces protective tissue memory that includes both humoral and cellular elements to protect specific tissue sites, such as the lung and lung-associated lymph nodes, against infection.
    1. Ivermectin was first identified in the 1970s during a veterinary drug screening project at Merck Pharmaceuticals. It was approved in 1981 for commercial use in veterinary medicine for parasitic infections in livestock and domestic pets with the brand name Mectizan. In the years since it was approved to treat river blindness, ivermectin was also shown to be highly effective against other parasitic infections.
    1. The evolution of the SARS-CoV-2 pandemic continuously produces new variants, which warrant timely epidemiological characterisation. Here we use the dense genomic surveillance generated by the COVID-19 Genomics UK Consortium to reconstruct the dynamics of 71 different lineages in each of 315 English local authorities between September 2020 and June 2021. This analysis reveals a series of sub-epidemics that peaked in the early autumn of 2020, followed by a jump in transmissibility of the B.1.1.7/Alpha lineage. Alpha grew when other lineages declined during the second national lockdown and regionally tiered restrictions between November and December 2020. A third more stringent national lockdown suppressed Alpha and eliminated nearly all other lineages in early 2021. However, a series of variants (mostly containing the spike E484K mutation) defied these trends and persisted at moderately increasing proportions. Accounting for sustained introductions, however, indicates that their transmissibility is unlikely to have exceeded that of Alpha. Finally, B.1.617.2/Delta was repeatedly introduced to England and grew rapidly in the early summer of 2021, constituting approximately 98% of sampled SARS-CoV-2 genomes on 26 June. Download PDF
    1. Campaigners have been gathering outside schools, handing out what they claim are legal documents or "notices of liability" to head teachers, warning them not to vaccinate children.
    1. The manuscript from Subramanian and Kumar shows a lack of vaccine efficacy on Covid Incidence. However, this paper suffers major pitfalls : inadequate outcome, lack of confounding factors, inadequate time period (7 days), inclusion/exclusion criteria not respected, causal inference from inappropriate data, and erroneous interpretation of the data. We comment on these issues in detail and show that Subramanian and Kumar’s paper is flawed and misleading.
    1. The B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in the state of Maharashtra in late 2020 and spread throughout India, outcompeting pre-existing lineages including B.1.617.1 (Kappa) and B.1.1.7 (Alpha)1. In vitro, B.1.617.2 is sixfold less sensitive to serum neutralizing antibodies from recovered individuals, and eightfold less sensitive to vaccine-elicited antibodies, compared with wild-type Wuhan-1 bearing D614G. Serum neutralizing titres against B.1.617.2 were lower in ChAdOx1 vaccinees than in BNT162b2 vaccinees. B.1.617.2 spike pseudotyped viruses exhibited compromised sensitivity to monoclonal antibodies to the receptor-binding domain and the amino-terminal domain. B.1.617.2 demonstrated higher replication efficiency than B.1.1.7 in both airway organoid and human airway epithelial systems, associated with B.1.617.2 spike being in a predominantly cleaved state compared with B.1.1.7 spike. The B.1.617.2 spike protein was able to mediate highly efficient syncytium formation that was less sensitive to inhibition by neutralizing antibody, compared with that of wild-type spike. We also observed that B.1.617.2 had higher replication and spike-mediated entry than B.1.617.1, potentially explaining the B.1.617.2 dominance. In an analysis of more than 130 SARS-CoV-2-infected health care workers across three centres in India during a period of mixed lineage circulation, we observed reduced ChAdOx1 vaccine effectiveness against B.1.617.2 relative to non-B.1.617.2, with the caveat of possible residual confounding. Compromised vaccine efficacy against the highly fit and immune-evasive B.1.617.2 Delta variant warrants continued infection control measures in the post-vaccination era.
    1. Gov. Abbott says he will pull the liquor license of any restaurant with vaccine requirements. This in a state out of beds in their ICUs.
    1. NEW DELHI: Indian Council of Medical Research (ICMR)-Covid-19 National Task Force Joint Monitoring Group dropped the usage of Ivermectin and Hydroxychloroquine (HCQ) drugs from revised clinical guidelines for the management of adult Covid-19 patients.
    1. Much confusion has been seen in the UK media about the effects on mortality of flu and covid-19. Gareth Iacobucci separates fact from fiction
    1. Lateral flow tests (LFTs) are very good at detecting people most likely to spread Covid-19 and positive results should be trusted, say University College London researchers.
    1. An unvaccinated child is at less risk of serious Covid illness than a vaccinated 70-year-old.
    1. After a rapid start, the pace of the United Kingdom’s (UK) covid-19 vaccination programme has slowed down while the UK still faces high infection, hospitalisation, and death rates, and a more transmissible Delta SARS-CoV-2 variant. Now that vaccination of children aged 12-15 has started, it is essential to achieve a high uptake of vaccination in this group, and also in young adults, to both protect them and to move the UK closer towards population level immunity. [1,2] Despite two doses of Pfizer-BioNTech, Moderna, and AstraZeneca vaccines offering good protection against the Delta variant—with Pfizer-BioNTech and AstraZeneca vaccines between 92-96% effective in preventing hospitalisations—many young people remain unvaccinated by choice, raising their risk of infection, hospitalisation, and long-term complications from covid-19. [3-5]
    1. So-called natural immunity varies from patient to patient, scientists say. Immunization is still the best choice after recovering from the disease.
    1. Health leaders must seize this historic opportunity to level upThe effect of the pandemic on non-covid related healthcare is only now starting to be felt by patients and healthcare systems. At least 4.5 million people are estimated to be waiting for elective care in the UK,1 and the backlog may rise to 13 million2 and take over a decade to clear. The backlog arose after a sharp fall in patient demand at the height of the first wave of the pandemic in the spring and summer of 2020 (driven by the instruction to stay at home to protect the NHS and a fear of coming to hospital) coupled with reduced capacity as resources were rightly allocated to meet the needs of people with covid-19.
    1. Science is about rational disagreement, the questioning and testing of orthodoxy and the constant search for truth. With something like lockdown – an untested policy that affects millions – rigorous debate and the basics of verification/falsification are more important than ever. Academics backing lockdown (or any major theory) ought to welcome challenges, knowing – as scientists do – that robust challenge is the way to identify error, improve policy and save lives.
    1. BACKGROUND Following administration to persons 60+ years of age, the booster vaccination campaign in Israel was gradually expanded to younger age groups who received a second dose >5 months earlier. We study the booster effect on COVID-19 outcomes.METHODS We extracted data for the period July 30, 2021 to October 6, 2021 from the Israeli Ministry of Health database regarding 4,621,836 persons. We compared confirmed Covid-19 infections, severe illness, and death of those who received a booster ≥12 days earlier (booster group) with a nonbooster group. In a secondary analysis, we compared the rates 3-7 days with ≥12 days after receiving the booster dose. We used Poisson regressions to estimate rate ratios after adjusting for possible confounding factors.RESULTS Confirmed infection rates were ≈10-fold lower in the booster versus nonbooster group (ranging 8.8-17.6 across five age groups) and 4.8-11.2 fold lower in the secondary analysis. Severe illness rates in the primary and secondary analysis were 18.7-fold (95% CI, 15.7-22.4) and 6.5-fold (95% CI, 5.1-8.3) lower for ages 60+, and 22.0-fold (95% CI, 10.3-47.0) and 3.2-fold (95% CI, 1.1-9.6) lower for ages 40-60. For ages 60+, COVID-19 associated death rates were 14.7-fold (95% CI, 9.4-23.1) lower in the primary analysis and 4.8-fold (95% CI, 2.8-8.2) lower in the secondary analysis.CONCLUSIONS Across all age groups, rates of confirmed infection and severe illness were substantially lower among those who received a booster dose of the BNT162b2 vaccine.
    1. Two studies from Israel quantify the risk of myocarditis following the Pfizer–BioNTech shot, with one suggesting the chance of developing the condition is about one in 50,000.
    1. A total of 49,158,835 people have now had their first dose of a coronavirus vaccine (85.5% of the population aged 12 and over), after a further 26,157 jabs were given yesterday.
    1. Sweden, Norway, and Finland suspended the use of Moderna’s covid-19 vaccine on 7 October after reports of possible rare side effects.The pause “for precautionary reasons” in Sweden and Finland concerns anyone born 1991 or later. In Finland, under 30s will now be offered the Pfizer vaccine as their second dose. Swedish officials are still discussing the second dose for the 81 000 under 30s who received a first dose of Moderna.In Norway officials have suspended the use of Moderna’s vaccine in those under 18, advising that they are offered the Pfizer vaccine instead.At a press conference on 6 October Anders Tegnell, epidemiologist at the Swedish Public Health Agency, explained that the suspension of the Moderna vaccine followed the detection of signals of an increased risk of side effects such as myocarditis and pericarditis.
    1. Six months after the second dose of the Pfizer-BioNTech covid-19 vaccine, antibody concentrations in healthcare workers had decreased substantially, especially among older men and immunosuppressed people, a study has found.1The Israeli researchers carried out a six month longitudinal prospective study that involved monthly antibody testing of around 4000 vaccinated healthcare workers. At six months the mixed-model analysis showed decreases in antibody concentrations of 38% for IgG antibodies and 42% for neutralising antibodies among those aged 65 years or older, when compared with participants aged 18-45. Decreases of 37% (IgG) and 46% (neutralising) were also seen in men 65 years of age or older when compared with women in the same age group.The study, published in the New England Journal of Medicine, reported that immunosuppressed people had decreases in antibody concentrations of 65% (IgG) and 70% (neutralising) compared with participants without immunosuppression, while people with a BMI of 30 or over had 31% higher neutralising antibody concentrations, when compared with those whose BMI was under 30.
    1. The emergence of SARS-CoV-2 variants with mutations in major neutralizing antibody-binding sites can affect humoral immunity induced by infection or vaccination1–6. We analysed the development of anti-SARS-CoV-2 antibody and T cell responses in previously infected (recovered) or uninfected (naive) individuals that received mRNA vaccines to SARS-CoV-2. While previously infected individuals sustained higher antibody titres than uninfected individuals post-vaccination, the latter reached comparable levels of neutralization responses to the ancestral strain after the second vaccine dose. T cell activation markers measured upon spike or nucleocapsid peptide in vitro stimulation showed a progressive increase after vaccination. Comprehensive analysis of plasma neutralization using 16 authentic isolates of distinct locally circulating SARS-CoV-2 variants revealed a range of reduction in the neutralization capacity associated with specific mutations in the spike gene: lineages with E484K and N501Y/T (e.g., B.1.351 and P.1) had the greatest reduction, followed by lineages with L452R (e.g., B.1.617.2). While both groups retained neutralization capacity against all variants, plasma from previously infected vaccinated individuals displayed overall better neutralization capacity when compared to plasma from uninfected individuals that also received two vaccine doses, pointing to vaccine boosters as a relevant future strategy to alleviate the impact of emerging variants on antibody neutralizing activity.